CA2140229A1 - N-cycloalkylpiperazine derivatives, methods of obtaining them and pharmaceutical compositions containing them - Google Patents
N-cycloalkylpiperazine derivatives, methods of obtaining them and pharmaceutical compositions containing themInfo
- Publication number
- CA2140229A1 CA2140229A1 CA002140229A CA2140229A CA2140229A1 CA 2140229 A1 CA2140229 A1 CA 2140229A1 CA 002140229 A CA002140229 A CA 002140229A CA 2140229 A CA2140229 A CA 2140229A CA 2140229 A1 CA2140229 A1 CA 2140229A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- derivatives
- pharmaceutically acceptable
- acid addition
- addition salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 125000005843 halogen group Chemical group 0.000 claims abstract description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 7
- 150000001408 amides Chemical class 0.000 claims abstract description 6
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 36
- 239000000460 chlorine Substances 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 25
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 24
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 235000009518 sodium iodide Nutrition 0.000 claims description 9
- 125000003368 amide group Chemical group 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000003849 aromatic solvent Substances 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
- 239000001358 L(+)-tartaric acid Substances 0.000 claims description 2
- 235000011002 L(+)-tartaric acid Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 12
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 claims 3
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000000243 solution Substances 0.000 description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 229960005141 piperazine Drugs 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 9
- 229960004046 apomorphine Drugs 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- -1 methanol or ethanol Chemical compound 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 5
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 206010042008 Stereotypy Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229940073584 methylene chloride Drugs 0.000 description 4
- 229940032007 methylethyl ketone Drugs 0.000 description 4
- 235000011837 pasties Nutrition 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- YIUUBOKMMYWIEG-UHFFFAOYSA-N 2-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]ethanamine Chemical compound C1CN(CCN)CCN1C1C2=CC=CC=C2CCC1 YIUUBOKMMYWIEG-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 3
- 229960002495 buspirone Drugs 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000701 neuroleptic effect Effects 0.000 description 3
- 150000004885 piperazines Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000002295 serotoninergic effect Effects 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- HOCPDSKONPQIQM-UHFFFAOYSA-N 4-(2-bromoethyl)isoindole-1,3-dione Chemical compound BrCCC1=CC=CC2=C1C(=O)NC2=O HOCPDSKONPQIQM-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 2
- 229940060037 fluorine Drugs 0.000 description 2
- 235000019000 fluorine Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000002182 synaptic membrane Anatomy 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- DLLBLNFCUXJHHV-UHFFFAOYSA-N 1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperazine Chemical compound C12=CC=CC=C2CCCC1N1CCNCC1 DLLBLNFCUXJHHV-UHFFFAOYSA-N 0.000 description 1
- DHULTAQUFRHOKU-UHFFFAOYSA-N 1-(2-chloroethyl)-4-fluorocyclohexa-2,4-diene-1-carboxamide Chemical compound ClCCC1(C(=O)N)CC=C(F)C=C1 DHULTAQUFRHOKU-UHFFFAOYSA-N 0.000 description 1
- URZAPYFJGQXLKY-UHFFFAOYSA-N 1-chloro-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC=C2C(Cl)CCCC2=C1 URZAPYFJGQXLKY-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- ATUPEPBRQNHPDY-UHFFFAOYSA-N 2-(4-benzylpiperazin-1-yl)acetonitrile Chemical compound C1CN(CC#N)CCN1CC1=CC=CC=C1 ATUPEPBRQNHPDY-UHFFFAOYSA-N 0.000 description 1
- CXEJMFLWEVKOGS-UHFFFAOYSA-N 2-(4-benzylpiperazin-1-yl)ethanamine Chemical compound C1CN(CCN)CCN1CC1=CC=CC=C1 CXEJMFLWEVKOGS-UHFFFAOYSA-N 0.000 description 1
- UVEFBIXRIMIWTK-UHFFFAOYSA-N 2-chloro-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC=C2CC(Cl)CCC2=C1 UVEFBIXRIMIWTK-UHFFFAOYSA-N 0.000 description 1
- RBGDLYUEXLWQBZ-UHFFFAOYSA-N 2-chlorobenzamide Chemical compound NC(=O)C1=CC=CC=C1Cl RBGDLYUEXLWQBZ-UHFFFAOYSA-N 0.000 description 1
- QHRZLTPFIFOPFT-UHFFFAOYSA-N 3-bromo-n-(4-fluorophenyl)propanamide Chemical compound FC1=CC=C(NC(=O)CCBr)C=C1 QHRZLTPFIFOPFT-UHFFFAOYSA-N 0.000 description 1
- IHBVNSPHKMCPST-UHFFFAOYSA-N 3-bromopropanoyl chloride Chemical compound ClC(=O)CCBr IHBVNSPHKMCPST-UHFFFAOYSA-N 0.000 description 1
- YUQHQHVGQQJUKU-UHFFFAOYSA-N 4-chloro-n-(1-piperazin-1-ylethyl)benzamide Chemical compound C1CNCCN1C(C)NC(=O)C1=CC=C(Cl)C=C1 YUQHQHVGQQJUKU-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- CPXKXLSFUJLYFN-UHFFFAOYSA-N 8-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC(O)=C2C(N(CCC)CCC)CCCC2=C1 CPXKXLSFUJLYFN-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- QEFCVFOMWYWUGJ-UHFFFAOYSA-N Cl.Cl.C(C1=CC=CC=C1)N1CCN(CC1)CCNC(C1=CC=C(C=C1)Cl)=O Chemical compound Cl.Cl.C(C1=CC=CC=C1)N1CCN(CC1)CCNC(C1=CC=C(C=C1)Cl)=O QEFCVFOMWYWUGJ-UHFFFAOYSA-N 0.000 description 1
- XVLGZQFTZPDKQI-UHFFFAOYSA-N Cl.Cl.C(C1=CC=CC=C1)N1CCN(CC1)CCNC(C1=CC=C(C=C1)F)=O Chemical compound Cl.Cl.C(C1=CC=CC=C1)N1CCN(CC1)CCNC(C1=CC=C(C=C1)F)=O XVLGZQFTZPDKQI-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 241001076084 Matus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102220630778 Presenilin-1_L14H_mutation Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- RFAZFSACZIVZDV-UHFFFAOYSA-N butan-2-one Chemical compound CCC(C)=O.CCC(C)=O RFAZFSACZIVZDV-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940057952 methanol Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102200046979 rs62645879 Human genes 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
N-CYCLOALKYLPIPERAZINE DERIVATIVES, METHODS OF OBTAIN-ING THEM AND PHARMAC~u~l~ICAL COMPOSITIONS CONTAINING
THEM
05 The present invention relates to N-cycloalkyl-piperazine derivatives, to their methods of preparation and to the pharmaceutical compositions in which they are present. The invention further relates to their use as pharmacological reagents.
The invention further relates to the levo-rotatory and dextrorotatory derivatives of the N-cyclo-alkylpiperazine compounds, to their preparation and to their use as pharmacological reagents.
The derivatives of the invention have valuable pharmacological properties, particularly neuroleptic properties, on the central nervous system.
The compounds of the invention are also good ligands for the 5-HTlA serotoninergic receptors and therefore possess antidepressant, antihypertensive, aggressolytic, analgesic and anxiolytic properties.
Compounds which act on the 5-HTlA receptors have already been described. In this connection, there may be mentioned patent application EP-A-0 434 561, which describes naphth-1-ylpiperazine derivatives, and patent application EP-A-0 466 585, which relates to piperidine derivatives having this type of activity.
It has also been demonstrated that 5-HTlA ago-nists reduce alcohol consumption in strains of alcohol-craving rats (Drug Dev. Res. 26, 319-341, 1992; Alcohol 6, 17-21, 1989; Alcohol 9, 283-6, 1992; Pharmacol.
Biochem. Behav. 34, 381-6, 1989; Alcohol 5, 147-152, 1988; Jpn. Psychiatr. Neurol. 46, 197-203, 1992), in monkeys (Alcohol 4, 49-56, 1987) and in man (Psycho-pathology 22 (suppl. 1), 49-59, 1989; J. Clin. Psycho-pharmacol. 9, 379-380, 1989).
~1~0229 The invention therefore relates to a novel family of compounds which have general formula (I) below:
(~c~ >~N N (C~ )A - A~ (I) E~
in which:
O O
- A is an amide group, -NH - C- or -C NH - , - R1, R2, R3, R4 and R5, which are identical or dif-ferent, are a hydrogen atom, a halogen atom, a C1_CG_ alkyl group, a C1-CG-alkoxy group, a trifluoromethyl group or a phenyl group, - m is an integer between 1 and 3, - n is an integer equal to 2 or 3.
In the present description:
- C1-C~-alkoxy denotes a hydroxyl group substituted by a C1-CG-alkyl; and - C1-CG-alkyl denotes straight-chain or branched-chain saturated aliphatic hydrocarbon radicals containing 1 to 6 carbon atoms. The preferred alkyl group is the methyl group.
The term "halogen" denotes the four halogens, F, Cl, Br and I. Preferably, if they are a halogen, R1, R2, R3, R4 and R5 are F or Cl.
Advantageous compounds of formula (I) are those in which at least one of the following conditions is fulfilled:
- A is an amide group -NH C- , 214022~
-- R3 is a hydrogen atom or a halogen atom, preferably fluorine or chlorine, - m = 2 or 3, - n = 2.
05 The preferred derivatives for the purposes of the invention are the racemic and levorotatory com-pounds which correspond to the above description and in which m is equal to 2.
The compounds of formula (I) can be obtained by condensing the substituted piperazines of formula (II) with the chlorinated derivatives of formula (III) below, in the presence of sodium or potassium carbonate and a catalytic amount of sodium or potassium iodide, in a ketone solvent such as methyl ethyl ketone (butan-2-one) or diethyl ketone.
Z ) C--A~ S
III II
In this reaction scheme, m, n, A, R1, R2, R3, R4 and R5 are as defined above.
The derivatives of the invention can also be prepared by condensing the monosubstituted N-cyclo-alkylpiperazines of formula (XV) with the halogenated amides of formula (VIII), in which X is a halogen atom, preferably chlorine or bromine, in an aromatic solvent such as benzene or toluene, or in dimethylformamide, in the presence of triethylamine or pyridine.
21~û229 ~ N~_~NH ~ .
XV VIII
The levorotatory and dextrorotatory derivatives of formula (I) are obtained in accordance with the above scheme from the resolved N-cycloalkylpiperazines of formula (XV). The resolution is effected by forming the diastereoisomeric salts with L-(+)-aspartic acid if it is desired to obtain the levorotatory compounds, or with L-(+)-tartaric acid if it is desired to obtain the dextrorotatory compounds.
The levorotatory or dextrorotatory derivatives of formula (I) in optically pure form are novel com-pounds forming part of the invention.
The compounds of formula (XV), in which m is as defined abov.e, are prepared by saponification and decarboxylation of the N-carboxylated piperazines of formula (XVI) with potassium hydroxide in an alcoholic medium in accordance with the following scheme:
~ KOH
m(H2C) ~_~N~ ~ m(H2C) N~--~
The compounds of formula (XVI) are easily obtained by condensing commercially available carbeth-oxypiperazine of formula (XVII) with the chlorinated derivatives of formula (III) in a mixture of methyl -ethyl ketone and DMF, in the presence of potassium carbonate and sodium iodide, in accordance with the following scheme:
~ + ~ O ~ XVI
m(H2C) Cl CH3 III XVII
The chlorinated derivatives of formula (III) can easily be obtained by chlorinating the correspon-ding alcohol of formula (IV), in which m is as definedabove, with thionyl chloride in an aromatic solvent such as benzene or toluene (BOGESO K.P. et al., J. Med.
Chem., 1983, 26(7), 944), or in a chlorinated solvent such as methylene chloride or chloroform:
N-~H ~ ~) 80Cl ~ ~
( N 2 C ) \~o ROH ~ ~ N 2 C ) \~ JlrH 2 Cl V IV III
The alcohols of formula (IV) are prepared by reducing the corresponding ketones of formula (V), which are commercially available, with sodium boro-hydride in an alcohol having from 1 to 6 carbon atoms, such as methanol or ethanol.
The piperazines of formula (II) are obtained by hydrogenolysis of the corresponding benzylated deriva-tives of formula (VI), in which n, A, Rl, R2, R3, R4 21~0229 and R5 are as defined above, in the presence of palla-dium-on-charcoal, in an alcohol such as methanol or ethanol, in accordance with the following scheme:
THEM
05 The present invention relates to N-cycloalkyl-piperazine derivatives, to their methods of preparation and to the pharmaceutical compositions in which they are present. The invention further relates to their use as pharmacological reagents.
The invention further relates to the levo-rotatory and dextrorotatory derivatives of the N-cyclo-alkylpiperazine compounds, to their preparation and to their use as pharmacological reagents.
The derivatives of the invention have valuable pharmacological properties, particularly neuroleptic properties, on the central nervous system.
The compounds of the invention are also good ligands for the 5-HTlA serotoninergic receptors and therefore possess antidepressant, antihypertensive, aggressolytic, analgesic and anxiolytic properties.
Compounds which act on the 5-HTlA receptors have already been described. In this connection, there may be mentioned patent application EP-A-0 434 561, which describes naphth-1-ylpiperazine derivatives, and patent application EP-A-0 466 585, which relates to piperidine derivatives having this type of activity.
It has also been demonstrated that 5-HTlA ago-nists reduce alcohol consumption in strains of alcohol-craving rats (Drug Dev. Res. 26, 319-341, 1992; Alcohol 6, 17-21, 1989; Alcohol 9, 283-6, 1992; Pharmacol.
Biochem. Behav. 34, 381-6, 1989; Alcohol 5, 147-152, 1988; Jpn. Psychiatr. Neurol. 46, 197-203, 1992), in monkeys (Alcohol 4, 49-56, 1987) and in man (Psycho-pathology 22 (suppl. 1), 49-59, 1989; J. Clin. Psycho-pharmacol. 9, 379-380, 1989).
~1~0229 The invention therefore relates to a novel family of compounds which have general formula (I) below:
(~c~ >~N N (C~ )A - A~ (I) E~
in which:
O O
- A is an amide group, -NH - C- or -C NH - , - R1, R2, R3, R4 and R5, which are identical or dif-ferent, are a hydrogen atom, a halogen atom, a C1_CG_ alkyl group, a C1-CG-alkoxy group, a trifluoromethyl group or a phenyl group, - m is an integer between 1 and 3, - n is an integer equal to 2 or 3.
In the present description:
- C1-C~-alkoxy denotes a hydroxyl group substituted by a C1-CG-alkyl; and - C1-CG-alkyl denotes straight-chain or branched-chain saturated aliphatic hydrocarbon radicals containing 1 to 6 carbon atoms. The preferred alkyl group is the methyl group.
The term "halogen" denotes the four halogens, F, Cl, Br and I. Preferably, if they are a halogen, R1, R2, R3, R4 and R5 are F or Cl.
Advantageous compounds of formula (I) are those in which at least one of the following conditions is fulfilled:
- A is an amide group -NH C- , 214022~
-- R3 is a hydrogen atom or a halogen atom, preferably fluorine or chlorine, - m = 2 or 3, - n = 2.
05 The preferred derivatives for the purposes of the invention are the racemic and levorotatory com-pounds which correspond to the above description and in which m is equal to 2.
The compounds of formula (I) can be obtained by condensing the substituted piperazines of formula (II) with the chlorinated derivatives of formula (III) below, in the presence of sodium or potassium carbonate and a catalytic amount of sodium or potassium iodide, in a ketone solvent such as methyl ethyl ketone (butan-2-one) or diethyl ketone.
Z ) C--A~ S
III II
In this reaction scheme, m, n, A, R1, R2, R3, R4 and R5 are as defined above.
The derivatives of the invention can also be prepared by condensing the monosubstituted N-cyclo-alkylpiperazines of formula (XV) with the halogenated amides of formula (VIII), in which X is a halogen atom, preferably chlorine or bromine, in an aromatic solvent such as benzene or toluene, or in dimethylformamide, in the presence of triethylamine or pyridine.
21~û229 ~ N~_~NH ~ .
XV VIII
The levorotatory and dextrorotatory derivatives of formula (I) are obtained in accordance with the above scheme from the resolved N-cycloalkylpiperazines of formula (XV). The resolution is effected by forming the diastereoisomeric salts with L-(+)-aspartic acid if it is desired to obtain the levorotatory compounds, or with L-(+)-tartaric acid if it is desired to obtain the dextrorotatory compounds.
The levorotatory or dextrorotatory derivatives of formula (I) in optically pure form are novel com-pounds forming part of the invention.
The compounds of formula (XV), in which m is as defined abov.e, are prepared by saponification and decarboxylation of the N-carboxylated piperazines of formula (XVI) with potassium hydroxide in an alcoholic medium in accordance with the following scheme:
~ KOH
m(H2C) ~_~N~ ~ m(H2C) N~--~
The compounds of formula (XVI) are easily obtained by condensing commercially available carbeth-oxypiperazine of formula (XVII) with the chlorinated derivatives of formula (III) in a mixture of methyl -ethyl ketone and DMF, in the presence of potassium carbonate and sodium iodide, in accordance with the following scheme:
~ + ~ O ~ XVI
m(H2C) Cl CH3 III XVII
The chlorinated derivatives of formula (III) can easily be obtained by chlorinating the correspon-ding alcohol of formula (IV), in which m is as definedabove, with thionyl chloride in an aromatic solvent such as benzene or toluene (BOGESO K.P. et al., J. Med.
Chem., 1983, 26(7), 944), or in a chlorinated solvent such as methylene chloride or chloroform:
N-~H ~ ~) 80Cl ~ ~
( N 2 C ) \~o ROH ~ ~ N 2 C ) \~ JlrH 2 Cl V IV III
The alcohols of formula (IV) are prepared by reducing the corresponding ketones of formula (V), which are commercially available, with sodium boro-hydride in an alcohol having from 1 to 6 carbon atoms, such as methanol or ethanol.
The piperazines of formula (II) are obtained by hydrogenolysis of the corresponding benzylated deriva-tives of formula (VI), in which n, A, Rl, R2, R3, R4 21~0229 and R5 are as defined above, in the presence of palla-dium-on-charcoal, in an alcohol such as methanol or ethanol, in accordance with the following scheme:
3~$A--(CH2~n N~JN 2~ H2 Pd/C ~$A--(CHz~n--N NH
R~, R5 R~ R5 Vl I~
The benzylated compounds of formula (VI) are prepared in conventional manner by reacting two equi-valents of 4-benzylpiperazine of formula (VII) with the halogenated amides of formula (VIII), in which X is as defined above, in dimethylformamide, in the presence of sodium or potassium iodide.
l~<R2 DMr \ ~
N NH ~ X--(CH2~n-A~R N N--(CH2~ A~R3 R5 R~ ~) R5 R~
V~l VIII
The derivatives of formula (VI) in which:
- n, Rl, R2, R3, R4 and Rs are as defined above, 1l - A is an amide group -NH C--~
can also be prepared by condensing the 4-benzyl-1~
aminoalkyl)piperazine of formula (IX) with the corres-ponding acid chlorides of formula (X). The reaction is carried out in an aromatic solvent such as benzene or toluene, in the presence of triethylamine.
~1~0229 /~~~ ArH
Cl ~ ~ N ~CH2)n~NH2 --------~ N N (CH2) The 4-benzyl-1-(~-aminoalkyl)piperazine of formula (IX) is obtained by reducing the 4-benzyl-1-(~-cyanoalkyl)piperazine of formula (XII) with lithium aluminum hydride (AlLiH4) in a solvent such as tetra-hydrofuran, in accordance with the following scheme:
~ AlLlH4 ~
/ = <--N N--(CH2)n-1--CN~ ~ = <--N N (CH2)n--NN2 ~ ~II ~ IX
The compound of formula (XII) is prepared in conventional manner by condensing the corresponding halogenonitrile of formula (XIII) with 4-benzylpipera-zine of formula (VII) in the presence of potassium or sodium carbonate, in dimethylformamide, X and n being as defined above.
2s ~ ~ NA2CO3 /--\
N NH ~ X (CH2)n-1-CN ~ ~ N N -(CH2)n-1-CN
VII XIII ~ XII
The halogenated amides of formula (VIII) below in which:
- n, R1, R2, R3, R4 and R5 are as defined above for the compounds of formula (I), Il .
- A is an amide group -C NH - , , - X is as defined above are obtained by reacting the anilines of formula (X) with the acid chlorides of formula (XI), in which X is a halogen atom, preferably a bromine or chlorine atom, 05 in an aromatic solvent such as benzene or toluene, in the presence of triethylamine, in accordance with the following reaction scheme:
x--( 0117 ) n ~ X~
~C ~CI VIII
The halogenated amides of formula (VIII) in which:
- n~ R1, R2, R3, R4 and R5 are as defined above for the compounds of formula (I), - A is an amide group -M~--C--, - X is as defined above can also be prepared by a conventional method of condensing the corresponding benzoyl chloride of formula (XIII) with the hydrohalides, especially the hydrochlorides, of the commercially available ~-halo-geno-l-alkylamines in a chlorinated solvent such as dichloromethane or chloroform, in the presence of one equivalent of sodium or potassium carbonate, in accor-dance with the following scheme:
~l~n.2~s 3~ 3 (CH23n X, X - 2C03 ~ R3 R" R5 R5 R~
XIII ~CIV VIII
The compounds (I~) of the invention, and more particularly the (-) levorotatory derivatives, in which:
- m and n are equal to 2, - A is an amide group -M~--C- , - R1, R2, R4 and R5 are a hydrogen atom, - R3 is a hydrogen atom or halogen atom, namely fluo-rine or chlorine, can be prepared with good yields by condensing the corresponding acid chlorides (XIII~) with racemic or levorotatory 1-[2-amino-1-ethyl]-4-[1,2,3,4-tetra-hydronaphth-l-yl]piperazine (XVIII) in a chlorinated solvent such as methylene chloride or chloroform, or in an aromatic solvent such as toluene or xylene, in the presence of triethylamine or pyridine.
~Cl 8-- --/ ~NN2 NN R3 N N
XIII- XVIII
The compound of formula (XVIII) is easily obtained by treating the corresponding phthalimide (XIX) with hydrazine in solution in an alcohol having from 1 to 6 carbon atoms, such as methanol or ethanol.
_f' 8--U N~ ~ N2N-IIN 2 ~---- ~ ~IIN~
XIX XVI I I
The phthalimide (XIX) results from condensing racemic or resolved l-(1,2,3,4-tetrahydronaphth-1-yl)-piperazine (XV~) with 2-chloro- or 2-bromo-ethylphtha-limide in a solvent such as DMF, acetonitrile or butan-2-one.
5 8~ ~n~ 8 N~ ~3 XIX
XV~
The acid addition salts of the derivatives of formula (I) according to the invention can be obtained by conventional methods with acids commonly used for obtaining pharmaceutically acceptable salts, such as hydrochloric, hydrobromic, maleic and fumaric acids.
Hydrochloric acid will preferably be used.
As indicated above, the derivatives of formula (I) possess valuable pharmacological properties on the central nervous system. They have an atypical neuro-leptic profile in animal pharmacology. Their affinity for the 5-HTlA serotoninergic receptors gives the derivatives according to the invention properties of the non-benzodiazepinic anxiolytic, antidepressant, antihypertensive, analgesic, aggressolytic and anti-alcoholic type.
The invention further relates to the pharma-21~0229 ceutical compositions in which a derivative of formula (I) is present as the active principle, in association with a pharmaceutically acceptable vehicle, and to the inclusion complexes such as those described especially 05 in Chem. Pharm. Bull., 1975, 23, 6, 1205; 1975, 23, 12, 3062; 1978, 26, 10, 2952. It will be advantageous to use the inclusion complexes of the compounds of the invention in ~-cyclodextrin.
The compositions according to the invention can be compositions capable of oral, sublingual, subcutane-ous, intramuscular, intravenous, transdermal, local or rectal administration.
The appropriate forms of administration include especially forms for oral administration, such as tablets, gelatin capsules, powders, granules and solutions or suspensions to be taken orally, forms for sublingual and buccal administration, forms for sub-cutaneous, intramuscular, intravenous, intranasal or intraocular administration and forms for rectal admini-stration.
According to another of its features, theinvention relates to the use of the derivatives of formula (I) as pharmacological reagents, either as such or labeled with radioactive or non-radioactive iso-topes, especially tritium or 1~C.
The invention will now be described in greaterdetail by means of the illustrative Examples below. In the Examples, the derivatives prepared were identified and characterized by studying their NMR and infrared spectra and by their elemental analysis.
Example 1 describes the preparation of a derivative of formula (I) in which n = 2, m = 2, A = - ~I C--, Rl, Rz, R~ and R5 = H, and R3 = Cl.
Example 2 describes the preparation of the (+) 21~0229 dextrorotatory derivative of this same compound. Exam-ple 3 describes a general method of preparing the racemic or optically pure (levorotatory or dextro-rotatory) derivatives of general formula (Ia) in which n = 2, m = 2, A = - ~I C-- , R1, R2, R4, R5 = H, and R3 = H, F, Cl.
Examples 4 to 16 relate to the preparation of intermediates which can be used for obtaining the derivatives of formula (I).
Preparation of 1-[2-(4-chlorobenzamido)-1-ethyll-4-(1,2,3,4-tetrahydronaphth-1-yl)piperazine dihydrochlo-ride ll (derivative I: n = 2, m = 2, A =-~I C-- Rl, R2, R~, R5 = H, R3 = Cl) A mixture of 1-[4-chlorobenzamido-2-ethyl]-piperazine (5 g - 0.018 M), 2-chlorotetralin (3.1 g -0.018 M), potassium carbonate (6.5 g - 0.047 M) and sodium iodide (2.8 g - 0.018 M) in 150 ml of methyl ethyl ketone is refluxed for 24 h.
The solvent is evaporated off to dryness, the residue is taken up with water and extracted with ethyl acetate and the extract is washed with acid and base to give 6.4 g of the crude base. Crude yield = 90%.
The product is purified on a silica column using AcOEt:Et3N 0.5% as the eluent to give 4.5 g of a white solid. Yield = 63%. M.p. = 130 C.
Preparation of the dihydrochloride The base is dissolved in alcohol, a solution of hydrogen chloride in alcohol is added and the salt crystallizes out. M.p. = 228 C.
. . , Preparation of (+)-1-~2-(4-chlorobenzamido)-1-ethyll-4-(1,2,3,4-tetrahydronaphth-1-yl)piperazine dihydro-chloride (derivative I: n = 2, m = 2, A = ~ ,Rl, R2, R
R5 = H, R3 = Cl) A mixture of (+)-1-(1,2,3,4-tetrahydronaphth-1-yl)piperazine (5.4 g - 0.025 M), N-(2-chloroethyl)-4-ll chlorobenzamide (VIII, n = 2, X = Cl, A =-~I C--, R1, R2, R4, R5 = H, R3 = Cl) (7 g - 0.032 M) and 8 ml of triethylamine in solution in 150 ml of DMF is heated at 60 C for 48 h, with stirring. After cooling the 15 reaction mixture is poured all at once into 200 ml of water and then extracted with ethyl acetate. The organic phase is dried over MgSO4, filtered and then evaporated under vacuum. The residual oil is chromato-graphed on silica using AcOEt/cyclohexane/Et3N 85/15/
0.4 as the eluent to give 3 g of a pure product.
Yield = 30%.
Preparation of the dihydrochloride The base is dissolved in alcohol, a solution of hydrogen chloride in alcohol is added and the salt 25 crystallizes out. M.p. = 232 C.
Preparation of levorotatory, dextrorotatory and racemic 1-[2-(benzamido)-1-ethyll-4-(1 2 3 4-tetrahydronaphth-1-yl)piperazine dihydrochloride In a 250 ml three-necked flask, a mixture of levorotatory, dextrorotatory or racemic 1-(2-amino-l-ethyl)-4-(1,2,3,4-tetrahydronaphth-1-yl)piperazine (0.01 M), triethylamine (2 ml) and 50 ml of chloroform is cooled to 5 C. Benzoyl chloride which is unsubsti-2l~a22s -tuted or substituted in the para position by a halogen atom (0.01 M) in 70 ml of chloroform is added dropwise to this mixture, the temperature being kept at or below 10 C.
05 When the addition is complete, the reaction mixture is stirred magnetically at room temperature for 4 hours. The solvent is evaporated off under vacuum, the residue is taken up with water and extracted with dichloromethane and the organic phase is washed with 2 N NaOH.
The product is purified on a silica column using AcOEt:Et3N 0.35% as the eluent.
(Stereochemistry), R3 (Levorotatory), Cl (Dextrorotatory), Cl (Racemic), Cl Yield87% 85% 85%
M.p.145 C 145 c 134 c (Levorotatory), H (Dextrorotatory), H (Racemic), H
Yield83% 82% 83%
M.p.147 C 147 C 94 C
(Levorotatory), F (Dextrorotatory), F (Racemic), F
Yield84% 86% 83%
M.p.142 C 142 C 145 C
Preparation of the dihydrochloride The base is dissolved in ethanol, a solution of hydrogen chloride in alcohol is added and the salt crystallizes out.
Compound (Stereochemistry) 8 (Levorotatory) 8 (Dextrorotatory) 8 (Racemic) M.p. 232 C 232 C 225 C
34 (Levorotatory) 34 (Dextrorotatory) 34 (Racemic) M.p. 215 C 215 C 232 C
2 (Levorotatory) 9 (Dextrorotatory) 9 (Racemic) M.p. 223 C 223 c 220 C
Preparation of 1-~2-(4-chlorobenzamido)-1-ethyl]piper-azine 05 (derivative II: n = 2, A = -NH - ~--,Rl, R2, R4, R5 =
H, R3 = Cl) l-Benzyl-4-[2-(4-chlorobenzamido)-1-ethyl]pipe-razine dihydrochloride (25 g - 0.06 M) is dissolved in a mixture of 100 ml of water + 100 ml of ethanol. 3 g of palladium-on-charcoal are added. Hydrogenolysis is carried out at room temperature.
The reaction mixture is filtered and the fil-trate is neutralized with 2 N sodium hydroxide and eva-porated to dryness. The product is taken up with dichloromethane, dried over magnesium sulfate and con-centrated under vacuum.
This gives 13 g of a pasty product. Yield =
81%.
Preparation of 4-benzyl-1-[2-(4-fluorobenzamido)-1-ethyl]piperazine dihydrochloride ll (derivative VI: n = 2, A =-NH ~-- Rl, R2, R~, R5 =
H, R3 = F) A mixture of benzylpiperazine (35.2 g - 0.2 M), sodium iodide (15 g - 0.1 M) and 150 ml of dimethyl-formamide is placed in a three-necked flask and a mixture of l-(2-chloroethyl)-4-fluorobenzamide (20.15 g - 0.1 M) and 50 ml of dimethylformamide is then added dropwise; the medium is stirred for 4 hours at room temperature and then for 2 hours at 60-70C.
After cooling, water is added and the mixture is extracted with ethyl acetate. The organic phase is washed several times with water, dried and then con-- 21 iO229 --centrated under vacuum to give 29 g of the crude base (yield = 85%). This base is dissolved in ethanol, a solution of hydrogen chloride in alcohol is then added and the dihydrochloride crystallizes out. 27.5 g of 05 dihydrochloride are obtained. Yield = 77.5%. M.p. =
201 C.
Preparation of N-~2-[(4-fluorophenylamino)carbonyl]-ethyl~-N'-~benzyl~piperazine dihydrochloride (derivative VI: n = 2, A = -C NH ,Rl, R2, R4, R5 H, R3 = F) A solution of 1-bromo-2-(4-fluorophenylamino)-carbonylethane (12.3 g - 0.05 M) in 30 ml of anhydrous dimethylformamide is added dropwise to a suspension of 4-benzylpiperazine (17.6 g - 0.1 M) and sodium iodide (7.5 g - 0.05 M) in 100 ml of anhydrous dimethylfor-mamide. The medium is stirred for 4 hours at room temperature and then for 2 hours at 60-70 C. After cooling, water is added and the mixture is extracted with ethyl acetate. The organic phase is washed several times with water, dried and then concentrated under vacuum to give 15 g of the crude base (yield =
87.9%). This base is dissolved in ethanol, a solution of hydrogen chloride in alcohol is then added and the dihydrochloride crystallizes out. 14 g of dihydro-chloride are obtained. Yield = 76.8%. M.p. = 226 C.
Preparation of 4-(benzyl)-1-(2-(4-chlorobenzamido)-1-ethyl)piperazine dihydrochloride ll (derivative VIa: n = 2, A =-NH C - ,Rl, R2, R~, R5 =
H, R3 = Cl) 21~02~9 .
A mixture of 4-chlorobenzoyl chloride (17.5 g -0.1 M) and 250 ml of benzene is placed in a three-necked flask. It is cooled to 5 C, 1-(benzyl)-4-[2-amino-l-ethyl]piperazine (20.5 g - 0.1 M) + 14 ml of 05 triethylamine + 50 ml of benzene are added dropwise at a temperature of 10 C or below and the mixture is then left to stand for 2 hours at room temperature. It is washed with water and then with a 10% solution of sodium hydroxide and the organic phase is dried over magnesium sulfate and then concentrated under vacuum to give 29.5 g of the crude base. Yield = 86%.
This base is dissolved in ethanol, a solution of hydrogen chloride in alcohol is then added and the dihydrochloride crystallizes out. 32 g of dihydro-chloride are obtained. Yield = 76.8%. M.p. = 209C.
Preparation of 4-(benzyl)-1-~2-amino-1-ethyl]piperazine (derivative IX, n = 2) In a three-necked flask, l-benzyl-4-(cyano-methyl)piperazine (10.5 g - 1.05 M) in solution in 100 ml of tetrahydrofuran is added dropwise, at a tempera-ture of 10 C or below, to a suspension of lithium aluminum hydride (2.6 g - 0.068 M) in tetrahydrofuran;
the mixture is then refluxed for 6 hours. It is cooled to 0 C and hydrolyzed by the dropwise addition of 3 ml of water and then 3 ml of 15% NaOH, still at a tempera-ture of 10 C or below; the solid is filtered off and washed with 2 times 100 ml of ethyl ether.
The filtrate is concentrated under vacuum and the oil obtained is taken up with 200 ml of ether; the ether solution is dried over MgSO4 and then concen-trated under vacuum.
This gives 8.6 g of product in the form of an oil. Yield = 80%.
21~0229 Preparation of 1-(benzyl)-4-(cyanomethyl)piperazine (derivative XII, n = 2) Potassium carbonate (17.6 g - 0.127 M), 100 ml 05 of dimethylformamide and 4-benzylpiperazine (17.6 g, 0.1 M) are placed in a three-necked flask and chloro-acetonitrile (9.06 g, 0.12 M) in 10 ml of dimethyl-formamide is then added dropwise; the temperature rises to 35 C.
After the addition, the mixture is stirred for 24 hours at room temperature.
100 ml of water are added and the mixture is extracted twice with 150 ml of ethyl acetate; the organic phase is washed twice with 150 ml of water and lS then once with 150 ml of a saturated solution of sodium chloride, dried over magnesium sulfate and then con-centrated under vacuum.
This gives 17.1 g of a thick oil. Yield: 85%.
Preparation of ~-bromo-N-(4-fluorophenyl)propionamide ll (derivative VIII, n = 2, X = Br, A = C NH ~ R
R2, R4, R5 = H, R3 = F) A mixture of 4-fluoroaniline (22.2 g - 0.2 M), 20 ml of triethylamine and 50 ml of benzene is placed in a three-necked flask and cooled to 5 C. 3-Bromo-propionyl chloride (34.3 g - 0.2 M) dissolved in 150 ml of benzene is then added dropwise. When the addition is complete, the reaction medium is left to stand at room temperature for 4 hours.
The benzene is evaporated off under vacuum.
The solid is taken up with dichloromethane and then washed with iced water. The organic phase is dried and then concentrated under vacuum to give 39 g of a solid.
21~û229 -. . .
Yield = 79%. M.p. = 115 C.
Preparation of 1-(2-chloroethyl)-4-fluorobenzamide (derivative VIII, n = 2, X = Cl, A = - ~I C - , Rl, Rz, R~, R5 = H, R3 = F) In a three-necked flask, 4-fluorobenzoyl chlo-ride (33.05 g - 0.21 M) dissolved in 50 ml of dichloro-methane is added dropwise to an aqueous solution ofchloroethylamine hydrochloride (26.60 g - 0.23 M) and potassium carbonate (37.4 g - 0.27 M). After stirring for 24 hours, the medium is extracted with dichloro-methane and the organic phase is dried and then concen-15 trated under vacuum to give 40 g of a solid. Yield =83.5%. M.p. = 108 C.
Preparation of 1-carbethoxy-4-(1,2,3,4-tetrahydro-20 naphth-1-yl)piperazine (derivative XVI: m = 2) Carbethoxypiperazine (317 g - 2 M), potassium carbonate (552 g - 4 M) and sodium iodide (100 g - 0.66 M) in solution in 1 l of methyl ethyl ketone (butan-2-25 one) and 400 ml of DMF are placed in a reactor. Chlo-rotetralin (302 g - 1.82 M) in solution in 400 ml of methyl ethyl ketone is added slowly. The mixture is refluxed for 24 hours.
After cooling, the mixture is filtered and the solvents are evaporated off. The residual oil is poured all at once into water and the product is extracted 3 times with ethyl acetate. The organic phase is concentrated and the residual oil is taken up with ethyl ether. A solution of hydrogen chloride in alcohol is then added. The hydrochloride formed is `_ -.
filtered off. The base is freed with sodium carbonate in a methylene chloride/water mixture. After decanta-tion, the organic phase is dried over MgSO4 and the solvent is evaporated off.
05 This gives 330 g of an oil. Yield = 63%.
Preparation of 1-(1,2,3,4-tetrahydronaphth-1-yl)-piperazine 1-Carbethoxy-4-(1,2,3,4-tetrahydronaphth-1-yl)-piperazine (330 g - 1.14 M) in solution in 1.2 1 of methanol and 300 ml of water is placed in a reactor.
Potassium hydroxide (840 g - 15 M) is added slowly.
The mixture is brought to the reflux point. The reac-tion is monitored by thin layer chromatography.
After the starting material has disappeared, the mixture is cooled, filtered and then extracted with dichloromethane. The solvent is evaporated off and the residual oil is taken up with ethanol. Oxalic acid is then added. The oxalate formed is filtered off and then freed with sodium carbonate in a methylene chlo-ride/water mixture. After decantation, the organic phase is dried over MgSO4 and the solvent is evaporated off under vacuum.
210 g of a pure oil are collected. Yield =
84%.
Resolution of 1-(1.2,3,4-tetrahydronaphth-1-yl)piper-azine 1. Treatment of the racemic amine with L-(+)-aspartic acid L-(+)-Aspartic acid (3.6 g - 0.027 M) is added to a solution of racemic amine (7.315 g - 0.0339 M) in 70 ml of 95% ethanol. The mixture is brought to the reflux point, stirred for a few minutes and then left to stand at room temperature for 3 to 4 hours. The precipitate formed is filtered off and dried in air to give 4.67 g of aspartate (39% based on the amine). The 05 filtrate is retained and treated as described below.
The solid obtained is decomposed with 150 ml of a 3 M
aqueous solution of sodium hydroxide. The aqueous phase is extracted with 3 times 150 ml of ethyl ether.
The organic phase is dried over MgSO4, filtered and evaporated under vacuum to give 1.915 g of impure (-)-amine in the form of an oil (26% of the initial amine).
[~]D25 = -114 (c = 1.64; 95% EtOH); enantiomeric excess (ee) 41%.
The mother liquors of the salt are evaporated to dryness to give 7.14 g of a product, which is treated with 240 ml of a 3 M aqueous solution of NaOH.
The aqueous phase is extracted with 3 times 200 ml of ethyl ether; the ether phase is dried over MgSO4, fil-tered and evaporated to dryness to give 5.02 g (69%) of impure (+)-amine in the form of an oil. [~]D25 = +50 (c = 1.38; 95% EtOH); ee 41%.
2. Purification of the levorotatory (-)-amine A solution of the impure (-)-amine (2.03 g -9.4 mM) in 80 ml of 95% ethanol is treated with oxalic acid dihydrate (1.2 g - 9.5 mM). A copious precipitate of oxalate forms very rapidly. The mixture is left to stand at room temperature for 1 to 2 hours and then filtered and the product is dried in air to give 2.2 g of (-)-oxalate. Yield = 76%; [~]D25 = -32 (c = 1.64;
H2O); melting point = 202-3 C; ee 100%.
The free amine is obtained by decomposing the oxalate with 3 M sodium hydroxide.
3. Preparation of the tartrate of the dextrorotatory (+)-amine A solution of impure (+)-amine (5 g - 0.023 M) 21~0229 , in 200 ml of 95% ethanol is treated with (+)-tartaric acid (3.47 g - 0.023 M). The mixture is heated to the reflux point and then left to stand at room temperature for about 3 hours. The precipitated tartrate is fil-05 tered off (5.5 g, 65%).
The tartrate thus obtained is decomposed with220 ml of 3 M sodium hydroxide. The aqueous phase is extracted with 3 times 200 ml of ethyl ether; the organic phase is dried over MgSO~, filtered and eva-porated to dryness to give 3.05 g of (+)-amine in the form of an oil. [~]D25 = +99 (c = 1.62; 95% EtOH); ee 81%.
4. Purification of the dextrorotatory (+)-amine The procedure is the same as for the levoro-tatory enantiomer, the oxalate of the (+)-amine being prepared by the addition of one equivalent of oxalic acid in 95% ethanol. The oxalate obtained is filtered off and then dried in air. Yield = 76%; [~]Dzs = +29 (c = 1.52; H2O); ee 97%.
The free amine is obtained by decomposing the oxalate with 3 M sodium hydroxide.
Preparation of levorotatory, dextrorotatory and racemic 1-(2-phthalimido-1-ethyl)-4-(1,2,3,4-tetrahydronaphth-1-yl)piperazine A mixture of levorotatory, dextrorotatory or racemic l-(1,2,3,4-tetrahydronaphth-1-yl)piperazine (10.8 g - 0.05 M), 2-bromoethylphthalimide (16.51 g -0.065 M), potassium carbonate (17.25 g - 0.125 M) and sodium iodide (1 g - 0.006 M) in 200 ml of acetonitrile is refluxed for 24 hours.
The solvent is evaporated off to dryness and the residue is taken up with water, extracted with ethyl acetate and washed with acid and base.
2I ~ 0229 --. . , The product is purified on a silica column using AcOEt/cyclohexane 35/65 as the eluent.
Levorotatory Dextrorotatory Racemic Yield 72% 73% 72%
05 M.p. 103 C 103 C 77 C
EX~I~PLE 16 Preparation of levorotatory, dextrorotatory and racemic 1-(2-amino-1-ethyl)-4-(1,2,3,4-tetrahydronaphth-1-yl)-piperazine A mixture of levorotatory, dextrorotatoryor racemic 1-(2-phthalimido-1-ethyl)-4-(1,2,3,4-tetra-hydronaphth-l-yl)piperazine (11.5 g - 0.029 M) and hydrazine hydrate (3.4 g - 0.068 M) in 200 ml of metha-nol is stirred magnetically at room temperature for 24hours.
The solvent is evaporated off under vacuum, 150 ml of 2 M HCl are added and the mixture is stirred magnetically for two hours. The solid formed is fil-tered off, the filtrate is neutralized with Na2CO3 andthe product is extracted with ethyl acetate to give a thick oil.
Levorotatory Dextrorotatory Racemic Yield 83% 79% 81%
The derivatives of formula (I) obtained from intermediates analogous to those of Examples 4 to 16, and containing the desired substituents, are collated in Table I below. Their yields and their melting points in the form of the base or a salt are reported in Table II below and their spectral data in Table III.
Derivatives of formula I
N l~(CH2 )n A~E~ (I) TABLE I
N- A n m R1 R2 R3 R4 Rs Empiricalformula NH-C0 2 1 H H Cl H HC22H26ClN3o NH-C0 2 1 H H ~ H HC2gH31N30 6 NH-C0 2 1 Cl H Cl H HCæH25Cl2N30 7 NH-C0 2 1 H0-CH3 0-CH3 0-CH3 HC2sH33N304 8 NH-C0 2 2 H H Cl H HC23H28ClN3 9 NH-C0 2 2 H H F H HC23H2gFN30 12 NH-C0 2 2 H H ~> H HC2gH33N30 13 NH-C0 2 2 Cl H Cl H HC23H27Cl2N3o NH-C0 2 3 H H Cl H HC24H30ClN30 17 NH-C0 2 3 H H aH3 H HC25H33N3 18 NH-C0 2 3 H H 0-CH3 H HC2sH33N302 19 NH-C0 2 3 H H <~ H HC30H35N30 NH-C0 2 3 Cl H Cl H HC24H29c12N3o 21 NH-C0 2 3 H0-CH3 0-CH3 0-CH3 HC~7H37N304 214022~
TABLE I ( continuation ) 24 NH-CO 3 3 H H F H HC2sH32FN3O
25 CO-NH 2 1 H H F H HCæH26FN3O
32 CO-NH 3 2 H H CF3 H HC2sH30F3N3 34 NH-CO 2 2 H H H H H C~H?gN3O
TABLE II
N- Yld 9~0 Mp~ C Mps C
S 75 153 2æ
9 54 145 æo Sl 134 210 11 56 149 l9S
lS 38 pasty 194 -.
TABLE II (continuation) 2152 pasty 214 24S5 oily 180 2954 oily 204 3053 pasty 236 3356,4oily 217 Mp" C: melting point of the base MPS C: melting point of the salt 2I~229 TABLE I I I
SPECTRAL DATA
IR ~cm~l) N- IH NMR (ppm) C= O NH
1 2,1(q,2H); 2,4-2,9(m,12H); 3,5(q,2H) 1633,5 3295 4,35(t,1H); 6,8 (NH); 7,1-7,9(DL8H) 2 2,1(q,2H); 2,4-3~mL12H);3,5(q,2H) 1634 3290,5 4,35(t,1H); 6,8~NH);7-7,9~mL8H) 3 2,1(q,2H); 2,37(s,3H); 2,5-3(~L12H); 3,5(q,2H) 1629,5 3299 4,35(t,1H); 6,8~NH); 7,1-7,8~mL8H) 4 2,1(q,2H); 2,4-3(m,12H); 3,5(q,2H); 3,8(s,3H) 1627 3320,7 4,3(t,1H); 6,8~NH); 6,8-7,8(m,8H) 2,1(q,2H); 2,4-3~mL12H); 3,5(q,2H); 1629 3295 4,35(t,1H); 6,8(NH); 7,2-8~mL13H) 6 2,1(q,2H); 2,45-3~mL12H); 3,5(q,2H) 1646,9 3280 4,3(t,1H); 6,9~NH); 7,1-7,7(nL7H) 7 2,1(q,2H); 2,4-3(m,12H); 3,5(q,2H) 1634 3283 3,85(s,qH); 4,3(t,1H); 6,8~NH); 7-7,4(m,6H) 8 1,85~L4H); 2,4-3~mL12H); 3,5(q,2H) 1633 3300 3,8(t,1H); 6,9(NH); 7-7,8(m,8H) 9 1,85~EL4H); 2,4-2,8(m,12H); 3,5(q,2H); 1634 3304 3,8(t,1H); 6,8~NH); 6,9-7,8(nl8H) 1,85(m,4H); 2,4(s,3H); 2,45-2,8(m,12H); 1632 3293 3,5(q,2H); 3,8(t,1H); 6,8(NH); 7-7,8(m,8H) 11 1,85(m,4H); 2,4-2,8(m,12H); 3,5(q,2H); 1627 3318 3,85(t,4H); 6,75(NH); 6,8-7,85(m,8H) 21~0229 -TABLE I I I ( continuation ) IR (cm~l) N- 'H NMR (ppm) C= O NH
12 1,85~EL4H);2,4-2,8~aL12H); 3,5(q,2H); 1635 3298 3,8(t,1H); 6,8(NH); 6,9-7,85(m,13H) 13 1,85(m,4H); 2,4-2,8~mL12H); 3,5(q,2H); 1635 3290 3,8(t,1H); 6,7~H); 6,9-7,8~EL7H) 14 1,85~EL4H~; 2,4-2,8~mL12H); 3,5(q,2H); 1634 3291 3.9(m,10H); 6,8(NH); 7-7,75 (m,6H) 1,5-2,2~CL6H~; 2,3-2,75(nL12H); 3,2(t,1H); 1639 3372 3,5(q,2H); 6,8(NH); 6,95-7,8(m,8H) 16 1,5-2,2(m,6H); 2,3-2,75(m,12H); 3,2(t,1H); 1643 3375 3,5(q,2H); 6,8(NH); 6,9-7,9(m,8H) 17 1,5-2,2~mL6H); 2,9(s,3H); 2,45-2,7~mL12H~; 1633 3312 3,2(t,1H); 3,5(q,2H~; 6,8(NH); 7-7,7~mL8H) 18 1,5-2,2~L6H); 2,4-2,75~mL12H); 3,2(t,1H); 1634 3341 3,5(q,2H); 3,85(s,3H); 6,6(NH); 6,8-7,85~EL8H) 19 1,5-2,2(m,6H); 2,4-2,8(m,12H); 3,2(t,1H); 1638 3350 3,5(q,2H); 6,8(NH); 6,9-7,9~mL13H) 1,5-2,2(m,6H); 2,4-2,8(m,12H); 3,2(t,1H); 1648 3443 3,5(q,2H); 6,9~NH); 7-7,75(m,7H) 21 1,5-2,2(m,6H); 2,4-2,75(m,12H); 3,2(t,1H); 1639 3363 3,5(q,2H); 3,9(s,9H); 6,9-7,25(m,7H~
22 1,65-2,2(m,4H); 2,4-3(EL12H); 3,5(q,2H); 1631 3344 4,3(t,1H); 6,85-7,95(m,8H); 8,4(NH~
23 1,65-2,15(m,6H); 2,4-2,95(m,12H); 1633 3321 3,4-4(m,3H); 6~9-8(m~8H); 8,45(NH) 21~02~9 TABLE III (continuation) IR (cm~l) N- 'H NMR (ppm) C= O NH
24 1,5-2,2~mL8H); 2,4-2,9(nL12H~; 1646 3334 3,1(t,1H); 3,5(q,2H); 6,95-7,95~mL8H); 8,4~NH) 2,1(q,2H); 2,4-3(m,14H); 4,4(t,1H); 1651 3285 6,8-7,6(nL8H); ll,OS~NH) 26 1,7-2,1(m,4H); 2,4-2,9(~L14H); 1654 3291 3,9(t,1H); 6,8-7,7(m,8H); ll,l~NH) 27 1,5-2,2~CL6H); 2,4-2,9~EL14H); 1683 3278 3,2(t,1H); 6,85-7,6(~L8H); ll,OS(NH) 28 1,7-2,15~m~4H); 2,35-3~14H); 4,3(t,1H); 1650 3277 6,85-7,6~mL8H); 9 (NH) 29 1,5-2,1~mL6H); 2,35-2,85~mL14H); 1646 3271 3,8(t,1H); 6,85-7,75(m,8H); 9,l~YH) 1,5-2,1~,8H); 2,3-2,8(m,14H); 1661 3261 3,2(t,1H); 6,85-7,7(m,8H); 9~NH) 31 1,6-2,15~mL4H); 2,4-2,9(~14H); 1686 3225 3,9(t,1H); 7-7,8(m8H); 11,45(NH) 32 1,5-2,15(~6H); 2,3-2,9~mL14H); 1667 3304 3,85(t,1H~; 7-7,8(m8H); 9,25(NH) 33 1,6-2,15(m,6H); 2,3(s,3H); 2,4-2,9(m,14H); 1655 3285 3,85(t,1H); 7-7,8(m,8H); 8,8(NH) 34 1,85(m,4H); 2,4-2,8(m,12H); 3,5(q,2H); 1636 3310 3,8(t,1H); 6,85(NH); 7-7,8(m,8H) 21~02~
PEIARMACOLOGICAL TESTS
The neuroleptic activity of the derivatives of formula (I) was evaluated by the following tests:
- Antagonism towards the effects induced by the injec-05 tion of 1 mg/kg of apomorphine (hypothermia, stereo-typies, redressments) - Increase in the immobility time in the tail suspen-sion test (TST) - Affinity (in vitro) for the D2 dopaminergic recep-tors.
As neuroleptics generally have a sedative and hypothermic character, the results obtained from the study of toxicity/Irwin symptoms will also be indicated in the Summary Table.
As correlations had been demonstrated between the anxiolytic activity of novel "non-benzodiazepinic"
derivatives, such as buspirone or ipsapirone, and their affinity for the 5-HTlA serotoninergic receptors, the compounds of the invention were evaluated on this basis. The values found on the other receptors are givenby way of indication and reflect the selectivity of the compounds of the invention.
1 - Interactions with apomorphine (1 mg/kg, administered subcutaneously) The test product is administered intraperi-toneally 60 min before the injection of apomorphine.
The apomorphine is injected subcutaneously at a rate of 1 mg/kg. The mice are then isolated in separate cages.
The redressments, the stereotypies (20 min after the injection of apomorphine) and the rectal tem-perature of the animals ( 30 min after the injection of apomorphine) are noted.
Conventional neuroleptics antagonize the symp-toms induced by apomorphine. Atypical neuroleptics can be ineffective on one or other of the three parameters, 21~022g or even on all three.
The results are expressed as follows:
- as the percentage change relative to the control for the redressments and the stereotypies, 05 - as the absolute change relative to the controls for the hypothermia.
The significance is indicated as follows: ns =
not significant; * = p < 0.05; ** = p < 0.01; *** = p <
0.001 according to the value of the Student test.
2 - Tail suspension test (TST) The tail suspension test described by STERU et al. (Prog. Neuropsycho. Pharmacol. Biol. Psychiat.
1987, 11, 659-671; Arch. Int. Pharmacodyn. Ther. 1987, 288 (1), 11-30) was prepared in order to detect psycho-tropic activities.
A rodent placed in an unpleasant situation withno obvious escape (suspended by the tail) rapidly reduces its evasive activity and then becomes immobile.
The test product is administered intraperi-toneally 60 min before the mouse is suspended.
Two parameters are measured:
- the period of immobility over 6 min - the power of the movements; this parameter, based on the energy expended by the animals, is independent of the duration of the activity.
10 animals are studied per dose. Antidepres-sants conventionally reduce the immobility time. Neu-roleptics tend to increase it.
The results are expressed as the percentage change relative to the untreated control.
The significance is indicated as follows: ns =
not significant; * = p < 0.05; ** = p < 0.01; *** = p <
O . 001 .
The results are reported in Table IV below:
21~02~9 -:
o C C~
c.~ E C * C C C C C c * * c * c * c O ~O ~ O ~ ~ o ~ ~ cr ~ cr~ ~ ~ ~O ~
+ + + + + + + + + +
~.
D C * C C C C C * C C * C * * *
a ~ ~ O ~ O ~
a ~+ ~+ ' ~+ ' ' ~+ ~+ + + ' ~+ + O+~ ~+
~ ~ ~ o o ~ ~ ~ `o ~ ~ ~t ~ l v~
~o ~ o o o o o o o o t` ~` o o t` l` o CL ~
~ -*c*****cc*c*c _ ~ ~ o o ~ ~; o o E- I I I + I + + I I + I I I I +
a .~
,_ C~ /
U~ ~
~ /
/ -Z
1'ABLE IV (continl~q~i!n.) TestsSedationHypothermia Dosetested Apomorphine TST
N- \ (i) (i) (ii) Hypoth.Redress.Stereotypy Immobility Power of movements 19 64 0 128 -1,4-C** 0% 13% +45% ns +10% ns 22 16 16 32 -2,5-C** 0% 6% +85%*~* -23% ns 23 64 16 32 -1,6-C ns 0% 0% +50%* +15% ns 24 16 32 32 -0,2-C ns 0% -6% +81%* -29% ,"
26 64 32 64 -2-C* * * 0% -13% +124%* * -12%
27 32 64 128 -0,1-C ns 0% 0% +51% ns +40%
29 32 32 64 -2,3-C*** -20% -13% +54% ns -44% ns 32 64 128 -1,0-C* 0% -41% +114%*** -46~o*
8 8 16 -0,3-C ns 0% -13% -8% ns +68%*
(i): dose in mg/kg at which activity appears in the Irwin test (ii): dosc tested in mg/kg (IP) in thc apomorphine and TST tests.
21~0229 -. . , 3 - Receptology The synaptic membranes are prepared by the method of JONES and MATUS (1980). The rats are decapi-tated and the brains (without the cerebellum) are 05 quickly removed.
The synaptic membranes are purified on a dis-continuous gradient of sucrose from a mitochondrial fraction lyzed by hypotonic shock, and are stored at The rat striatum membranes are prepared from different striata under the same conditions.
The membranes (100 ~g of proteins) are incu-bated in the presence of radioligands under the fol-lowing conditions reported in Table V below:
TABLE V
Receptor Labeled ligand Concentration Incubation (conditions) ~1 (3H) Prazozine0.25 nM 30 min/25 C
D2 (3H) Haloperidol 1 nM 45 min/25 C
R~, R5 R~ R5 Vl I~
The benzylated compounds of formula (VI) are prepared in conventional manner by reacting two equi-valents of 4-benzylpiperazine of formula (VII) with the halogenated amides of formula (VIII), in which X is as defined above, in dimethylformamide, in the presence of sodium or potassium iodide.
l~<R2 DMr \ ~
N NH ~ X--(CH2~n-A~R N N--(CH2~ A~R3 R5 R~ ~) R5 R~
V~l VIII
The derivatives of formula (VI) in which:
- n, Rl, R2, R3, R4 and Rs are as defined above, 1l - A is an amide group -NH C--~
can also be prepared by condensing the 4-benzyl-1~
aminoalkyl)piperazine of formula (IX) with the corres-ponding acid chlorides of formula (X). The reaction is carried out in an aromatic solvent such as benzene or toluene, in the presence of triethylamine.
~1~0229 /~~~ ArH
Cl ~ ~ N ~CH2)n~NH2 --------~ N N (CH2) The 4-benzyl-1-(~-aminoalkyl)piperazine of formula (IX) is obtained by reducing the 4-benzyl-1-(~-cyanoalkyl)piperazine of formula (XII) with lithium aluminum hydride (AlLiH4) in a solvent such as tetra-hydrofuran, in accordance with the following scheme:
~ AlLlH4 ~
/ = <--N N--(CH2)n-1--CN~ ~ = <--N N (CH2)n--NN2 ~ ~II ~ IX
The compound of formula (XII) is prepared in conventional manner by condensing the corresponding halogenonitrile of formula (XIII) with 4-benzylpipera-zine of formula (VII) in the presence of potassium or sodium carbonate, in dimethylformamide, X and n being as defined above.
2s ~ ~ NA2CO3 /--\
N NH ~ X (CH2)n-1-CN ~ ~ N N -(CH2)n-1-CN
VII XIII ~ XII
The halogenated amides of formula (VIII) below in which:
- n, R1, R2, R3, R4 and R5 are as defined above for the compounds of formula (I), Il .
- A is an amide group -C NH - , , - X is as defined above are obtained by reacting the anilines of formula (X) with the acid chlorides of formula (XI), in which X is a halogen atom, preferably a bromine or chlorine atom, 05 in an aromatic solvent such as benzene or toluene, in the presence of triethylamine, in accordance with the following reaction scheme:
x--( 0117 ) n ~ X~
~C ~CI VIII
The halogenated amides of formula (VIII) in which:
- n~ R1, R2, R3, R4 and R5 are as defined above for the compounds of formula (I), - A is an amide group -M~--C--, - X is as defined above can also be prepared by a conventional method of condensing the corresponding benzoyl chloride of formula (XIII) with the hydrohalides, especially the hydrochlorides, of the commercially available ~-halo-geno-l-alkylamines in a chlorinated solvent such as dichloromethane or chloroform, in the presence of one equivalent of sodium or potassium carbonate, in accor-dance with the following scheme:
~l~n.2~s 3~ 3 (CH23n X, X - 2C03 ~ R3 R" R5 R5 R~
XIII ~CIV VIII
The compounds (I~) of the invention, and more particularly the (-) levorotatory derivatives, in which:
- m and n are equal to 2, - A is an amide group -M~--C- , - R1, R2, R4 and R5 are a hydrogen atom, - R3 is a hydrogen atom or halogen atom, namely fluo-rine or chlorine, can be prepared with good yields by condensing the corresponding acid chlorides (XIII~) with racemic or levorotatory 1-[2-amino-1-ethyl]-4-[1,2,3,4-tetra-hydronaphth-l-yl]piperazine (XVIII) in a chlorinated solvent such as methylene chloride or chloroform, or in an aromatic solvent such as toluene or xylene, in the presence of triethylamine or pyridine.
~Cl 8-- --/ ~NN2 NN R3 N N
XIII- XVIII
The compound of formula (XVIII) is easily obtained by treating the corresponding phthalimide (XIX) with hydrazine in solution in an alcohol having from 1 to 6 carbon atoms, such as methanol or ethanol.
_f' 8--U N~ ~ N2N-IIN 2 ~---- ~ ~IIN~
XIX XVI I I
The phthalimide (XIX) results from condensing racemic or resolved l-(1,2,3,4-tetrahydronaphth-1-yl)-piperazine (XV~) with 2-chloro- or 2-bromo-ethylphtha-limide in a solvent such as DMF, acetonitrile or butan-2-one.
5 8~ ~n~ 8 N~ ~3 XIX
XV~
The acid addition salts of the derivatives of formula (I) according to the invention can be obtained by conventional methods with acids commonly used for obtaining pharmaceutically acceptable salts, such as hydrochloric, hydrobromic, maleic and fumaric acids.
Hydrochloric acid will preferably be used.
As indicated above, the derivatives of formula (I) possess valuable pharmacological properties on the central nervous system. They have an atypical neuro-leptic profile in animal pharmacology. Their affinity for the 5-HTlA serotoninergic receptors gives the derivatives according to the invention properties of the non-benzodiazepinic anxiolytic, antidepressant, antihypertensive, analgesic, aggressolytic and anti-alcoholic type.
The invention further relates to the pharma-21~0229 ceutical compositions in which a derivative of formula (I) is present as the active principle, in association with a pharmaceutically acceptable vehicle, and to the inclusion complexes such as those described especially 05 in Chem. Pharm. Bull., 1975, 23, 6, 1205; 1975, 23, 12, 3062; 1978, 26, 10, 2952. It will be advantageous to use the inclusion complexes of the compounds of the invention in ~-cyclodextrin.
The compositions according to the invention can be compositions capable of oral, sublingual, subcutane-ous, intramuscular, intravenous, transdermal, local or rectal administration.
The appropriate forms of administration include especially forms for oral administration, such as tablets, gelatin capsules, powders, granules and solutions or suspensions to be taken orally, forms for sublingual and buccal administration, forms for sub-cutaneous, intramuscular, intravenous, intranasal or intraocular administration and forms for rectal admini-stration.
According to another of its features, theinvention relates to the use of the derivatives of formula (I) as pharmacological reagents, either as such or labeled with radioactive or non-radioactive iso-topes, especially tritium or 1~C.
The invention will now be described in greaterdetail by means of the illustrative Examples below. In the Examples, the derivatives prepared were identified and characterized by studying their NMR and infrared spectra and by their elemental analysis.
Example 1 describes the preparation of a derivative of formula (I) in which n = 2, m = 2, A = - ~I C--, Rl, Rz, R~ and R5 = H, and R3 = Cl.
Example 2 describes the preparation of the (+) 21~0229 dextrorotatory derivative of this same compound. Exam-ple 3 describes a general method of preparing the racemic or optically pure (levorotatory or dextro-rotatory) derivatives of general formula (Ia) in which n = 2, m = 2, A = - ~I C-- , R1, R2, R4, R5 = H, and R3 = H, F, Cl.
Examples 4 to 16 relate to the preparation of intermediates which can be used for obtaining the derivatives of formula (I).
Preparation of 1-[2-(4-chlorobenzamido)-1-ethyll-4-(1,2,3,4-tetrahydronaphth-1-yl)piperazine dihydrochlo-ride ll (derivative I: n = 2, m = 2, A =-~I C-- Rl, R2, R~, R5 = H, R3 = Cl) A mixture of 1-[4-chlorobenzamido-2-ethyl]-piperazine (5 g - 0.018 M), 2-chlorotetralin (3.1 g -0.018 M), potassium carbonate (6.5 g - 0.047 M) and sodium iodide (2.8 g - 0.018 M) in 150 ml of methyl ethyl ketone is refluxed for 24 h.
The solvent is evaporated off to dryness, the residue is taken up with water and extracted with ethyl acetate and the extract is washed with acid and base to give 6.4 g of the crude base. Crude yield = 90%.
The product is purified on a silica column using AcOEt:Et3N 0.5% as the eluent to give 4.5 g of a white solid. Yield = 63%. M.p. = 130 C.
Preparation of the dihydrochloride The base is dissolved in alcohol, a solution of hydrogen chloride in alcohol is added and the salt crystallizes out. M.p. = 228 C.
. . , Preparation of (+)-1-~2-(4-chlorobenzamido)-1-ethyll-4-(1,2,3,4-tetrahydronaphth-1-yl)piperazine dihydro-chloride (derivative I: n = 2, m = 2, A = ~ ,Rl, R2, R
R5 = H, R3 = Cl) A mixture of (+)-1-(1,2,3,4-tetrahydronaphth-1-yl)piperazine (5.4 g - 0.025 M), N-(2-chloroethyl)-4-ll chlorobenzamide (VIII, n = 2, X = Cl, A =-~I C--, R1, R2, R4, R5 = H, R3 = Cl) (7 g - 0.032 M) and 8 ml of triethylamine in solution in 150 ml of DMF is heated at 60 C for 48 h, with stirring. After cooling the 15 reaction mixture is poured all at once into 200 ml of water and then extracted with ethyl acetate. The organic phase is dried over MgSO4, filtered and then evaporated under vacuum. The residual oil is chromato-graphed on silica using AcOEt/cyclohexane/Et3N 85/15/
0.4 as the eluent to give 3 g of a pure product.
Yield = 30%.
Preparation of the dihydrochloride The base is dissolved in alcohol, a solution of hydrogen chloride in alcohol is added and the salt 25 crystallizes out. M.p. = 232 C.
Preparation of levorotatory, dextrorotatory and racemic 1-[2-(benzamido)-1-ethyll-4-(1 2 3 4-tetrahydronaphth-1-yl)piperazine dihydrochloride In a 250 ml three-necked flask, a mixture of levorotatory, dextrorotatory or racemic 1-(2-amino-l-ethyl)-4-(1,2,3,4-tetrahydronaphth-1-yl)piperazine (0.01 M), triethylamine (2 ml) and 50 ml of chloroform is cooled to 5 C. Benzoyl chloride which is unsubsti-2l~a22s -tuted or substituted in the para position by a halogen atom (0.01 M) in 70 ml of chloroform is added dropwise to this mixture, the temperature being kept at or below 10 C.
05 When the addition is complete, the reaction mixture is stirred magnetically at room temperature for 4 hours. The solvent is evaporated off under vacuum, the residue is taken up with water and extracted with dichloromethane and the organic phase is washed with 2 N NaOH.
The product is purified on a silica column using AcOEt:Et3N 0.35% as the eluent.
(Stereochemistry), R3 (Levorotatory), Cl (Dextrorotatory), Cl (Racemic), Cl Yield87% 85% 85%
M.p.145 C 145 c 134 c (Levorotatory), H (Dextrorotatory), H (Racemic), H
Yield83% 82% 83%
M.p.147 C 147 C 94 C
(Levorotatory), F (Dextrorotatory), F (Racemic), F
Yield84% 86% 83%
M.p.142 C 142 C 145 C
Preparation of the dihydrochloride The base is dissolved in ethanol, a solution of hydrogen chloride in alcohol is added and the salt crystallizes out.
Compound (Stereochemistry) 8 (Levorotatory) 8 (Dextrorotatory) 8 (Racemic) M.p. 232 C 232 C 225 C
34 (Levorotatory) 34 (Dextrorotatory) 34 (Racemic) M.p. 215 C 215 C 232 C
2 (Levorotatory) 9 (Dextrorotatory) 9 (Racemic) M.p. 223 C 223 c 220 C
Preparation of 1-~2-(4-chlorobenzamido)-1-ethyl]piper-azine 05 (derivative II: n = 2, A = -NH - ~--,Rl, R2, R4, R5 =
H, R3 = Cl) l-Benzyl-4-[2-(4-chlorobenzamido)-1-ethyl]pipe-razine dihydrochloride (25 g - 0.06 M) is dissolved in a mixture of 100 ml of water + 100 ml of ethanol. 3 g of palladium-on-charcoal are added. Hydrogenolysis is carried out at room temperature.
The reaction mixture is filtered and the fil-trate is neutralized with 2 N sodium hydroxide and eva-porated to dryness. The product is taken up with dichloromethane, dried over magnesium sulfate and con-centrated under vacuum.
This gives 13 g of a pasty product. Yield =
81%.
Preparation of 4-benzyl-1-[2-(4-fluorobenzamido)-1-ethyl]piperazine dihydrochloride ll (derivative VI: n = 2, A =-NH ~-- Rl, R2, R~, R5 =
H, R3 = F) A mixture of benzylpiperazine (35.2 g - 0.2 M), sodium iodide (15 g - 0.1 M) and 150 ml of dimethyl-formamide is placed in a three-necked flask and a mixture of l-(2-chloroethyl)-4-fluorobenzamide (20.15 g - 0.1 M) and 50 ml of dimethylformamide is then added dropwise; the medium is stirred for 4 hours at room temperature and then for 2 hours at 60-70C.
After cooling, water is added and the mixture is extracted with ethyl acetate. The organic phase is washed several times with water, dried and then con-- 21 iO229 --centrated under vacuum to give 29 g of the crude base (yield = 85%). This base is dissolved in ethanol, a solution of hydrogen chloride in alcohol is then added and the dihydrochloride crystallizes out. 27.5 g of 05 dihydrochloride are obtained. Yield = 77.5%. M.p. =
201 C.
Preparation of N-~2-[(4-fluorophenylamino)carbonyl]-ethyl~-N'-~benzyl~piperazine dihydrochloride (derivative VI: n = 2, A = -C NH ,Rl, R2, R4, R5 H, R3 = F) A solution of 1-bromo-2-(4-fluorophenylamino)-carbonylethane (12.3 g - 0.05 M) in 30 ml of anhydrous dimethylformamide is added dropwise to a suspension of 4-benzylpiperazine (17.6 g - 0.1 M) and sodium iodide (7.5 g - 0.05 M) in 100 ml of anhydrous dimethylfor-mamide. The medium is stirred for 4 hours at room temperature and then for 2 hours at 60-70 C. After cooling, water is added and the mixture is extracted with ethyl acetate. The organic phase is washed several times with water, dried and then concentrated under vacuum to give 15 g of the crude base (yield =
87.9%). This base is dissolved in ethanol, a solution of hydrogen chloride in alcohol is then added and the dihydrochloride crystallizes out. 14 g of dihydro-chloride are obtained. Yield = 76.8%. M.p. = 226 C.
Preparation of 4-(benzyl)-1-(2-(4-chlorobenzamido)-1-ethyl)piperazine dihydrochloride ll (derivative VIa: n = 2, A =-NH C - ,Rl, R2, R~, R5 =
H, R3 = Cl) 21~02~9 .
A mixture of 4-chlorobenzoyl chloride (17.5 g -0.1 M) and 250 ml of benzene is placed in a three-necked flask. It is cooled to 5 C, 1-(benzyl)-4-[2-amino-l-ethyl]piperazine (20.5 g - 0.1 M) + 14 ml of 05 triethylamine + 50 ml of benzene are added dropwise at a temperature of 10 C or below and the mixture is then left to stand for 2 hours at room temperature. It is washed with water and then with a 10% solution of sodium hydroxide and the organic phase is dried over magnesium sulfate and then concentrated under vacuum to give 29.5 g of the crude base. Yield = 86%.
This base is dissolved in ethanol, a solution of hydrogen chloride in alcohol is then added and the dihydrochloride crystallizes out. 32 g of dihydro-chloride are obtained. Yield = 76.8%. M.p. = 209C.
Preparation of 4-(benzyl)-1-~2-amino-1-ethyl]piperazine (derivative IX, n = 2) In a three-necked flask, l-benzyl-4-(cyano-methyl)piperazine (10.5 g - 1.05 M) in solution in 100 ml of tetrahydrofuran is added dropwise, at a tempera-ture of 10 C or below, to a suspension of lithium aluminum hydride (2.6 g - 0.068 M) in tetrahydrofuran;
the mixture is then refluxed for 6 hours. It is cooled to 0 C and hydrolyzed by the dropwise addition of 3 ml of water and then 3 ml of 15% NaOH, still at a tempera-ture of 10 C or below; the solid is filtered off and washed with 2 times 100 ml of ethyl ether.
The filtrate is concentrated under vacuum and the oil obtained is taken up with 200 ml of ether; the ether solution is dried over MgSO4 and then concen-trated under vacuum.
This gives 8.6 g of product in the form of an oil. Yield = 80%.
21~0229 Preparation of 1-(benzyl)-4-(cyanomethyl)piperazine (derivative XII, n = 2) Potassium carbonate (17.6 g - 0.127 M), 100 ml 05 of dimethylformamide and 4-benzylpiperazine (17.6 g, 0.1 M) are placed in a three-necked flask and chloro-acetonitrile (9.06 g, 0.12 M) in 10 ml of dimethyl-formamide is then added dropwise; the temperature rises to 35 C.
After the addition, the mixture is stirred for 24 hours at room temperature.
100 ml of water are added and the mixture is extracted twice with 150 ml of ethyl acetate; the organic phase is washed twice with 150 ml of water and lS then once with 150 ml of a saturated solution of sodium chloride, dried over magnesium sulfate and then con-centrated under vacuum.
This gives 17.1 g of a thick oil. Yield: 85%.
Preparation of ~-bromo-N-(4-fluorophenyl)propionamide ll (derivative VIII, n = 2, X = Br, A = C NH ~ R
R2, R4, R5 = H, R3 = F) A mixture of 4-fluoroaniline (22.2 g - 0.2 M), 20 ml of triethylamine and 50 ml of benzene is placed in a three-necked flask and cooled to 5 C. 3-Bromo-propionyl chloride (34.3 g - 0.2 M) dissolved in 150 ml of benzene is then added dropwise. When the addition is complete, the reaction medium is left to stand at room temperature for 4 hours.
The benzene is evaporated off under vacuum.
The solid is taken up with dichloromethane and then washed with iced water. The organic phase is dried and then concentrated under vacuum to give 39 g of a solid.
21~û229 -. . .
Yield = 79%. M.p. = 115 C.
Preparation of 1-(2-chloroethyl)-4-fluorobenzamide (derivative VIII, n = 2, X = Cl, A = - ~I C - , Rl, Rz, R~, R5 = H, R3 = F) In a three-necked flask, 4-fluorobenzoyl chlo-ride (33.05 g - 0.21 M) dissolved in 50 ml of dichloro-methane is added dropwise to an aqueous solution ofchloroethylamine hydrochloride (26.60 g - 0.23 M) and potassium carbonate (37.4 g - 0.27 M). After stirring for 24 hours, the medium is extracted with dichloro-methane and the organic phase is dried and then concen-15 trated under vacuum to give 40 g of a solid. Yield =83.5%. M.p. = 108 C.
Preparation of 1-carbethoxy-4-(1,2,3,4-tetrahydro-20 naphth-1-yl)piperazine (derivative XVI: m = 2) Carbethoxypiperazine (317 g - 2 M), potassium carbonate (552 g - 4 M) and sodium iodide (100 g - 0.66 M) in solution in 1 l of methyl ethyl ketone (butan-2-25 one) and 400 ml of DMF are placed in a reactor. Chlo-rotetralin (302 g - 1.82 M) in solution in 400 ml of methyl ethyl ketone is added slowly. The mixture is refluxed for 24 hours.
After cooling, the mixture is filtered and the solvents are evaporated off. The residual oil is poured all at once into water and the product is extracted 3 times with ethyl acetate. The organic phase is concentrated and the residual oil is taken up with ethyl ether. A solution of hydrogen chloride in alcohol is then added. The hydrochloride formed is `_ -.
filtered off. The base is freed with sodium carbonate in a methylene chloride/water mixture. After decanta-tion, the organic phase is dried over MgSO4 and the solvent is evaporated off.
05 This gives 330 g of an oil. Yield = 63%.
Preparation of 1-(1,2,3,4-tetrahydronaphth-1-yl)-piperazine 1-Carbethoxy-4-(1,2,3,4-tetrahydronaphth-1-yl)-piperazine (330 g - 1.14 M) in solution in 1.2 1 of methanol and 300 ml of water is placed in a reactor.
Potassium hydroxide (840 g - 15 M) is added slowly.
The mixture is brought to the reflux point. The reac-tion is monitored by thin layer chromatography.
After the starting material has disappeared, the mixture is cooled, filtered and then extracted with dichloromethane. The solvent is evaporated off and the residual oil is taken up with ethanol. Oxalic acid is then added. The oxalate formed is filtered off and then freed with sodium carbonate in a methylene chlo-ride/water mixture. After decantation, the organic phase is dried over MgSO4 and the solvent is evaporated off under vacuum.
210 g of a pure oil are collected. Yield =
84%.
Resolution of 1-(1.2,3,4-tetrahydronaphth-1-yl)piper-azine 1. Treatment of the racemic amine with L-(+)-aspartic acid L-(+)-Aspartic acid (3.6 g - 0.027 M) is added to a solution of racemic amine (7.315 g - 0.0339 M) in 70 ml of 95% ethanol. The mixture is brought to the reflux point, stirred for a few minutes and then left to stand at room temperature for 3 to 4 hours. The precipitate formed is filtered off and dried in air to give 4.67 g of aspartate (39% based on the amine). The 05 filtrate is retained and treated as described below.
The solid obtained is decomposed with 150 ml of a 3 M
aqueous solution of sodium hydroxide. The aqueous phase is extracted with 3 times 150 ml of ethyl ether.
The organic phase is dried over MgSO4, filtered and evaporated under vacuum to give 1.915 g of impure (-)-amine in the form of an oil (26% of the initial amine).
[~]D25 = -114 (c = 1.64; 95% EtOH); enantiomeric excess (ee) 41%.
The mother liquors of the salt are evaporated to dryness to give 7.14 g of a product, which is treated with 240 ml of a 3 M aqueous solution of NaOH.
The aqueous phase is extracted with 3 times 200 ml of ethyl ether; the ether phase is dried over MgSO4, fil-tered and evaporated to dryness to give 5.02 g (69%) of impure (+)-amine in the form of an oil. [~]D25 = +50 (c = 1.38; 95% EtOH); ee 41%.
2. Purification of the levorotatory (-)-amine A solution of the impure (-)-amine (2.03 g -9.4 mM) in 80 ml of 95% ethanol is treated with oxalic acid dihydrate (1.2 g - 9.5 mM). A copious precipitate of oxalate forms very rapidly. The mixture is left to stand at room temperature for 1 to 2 hours and then filtered and the product is dried in air to give 2.2 g of (-)-oxalate. Yield = 76%; [~]D25 = -32 (c = 1.64;
H2O); melting point = 202-3 C; ee 100%.
The free amine is obtained by decomposing the oxalate with 3 M sodium hydroxide.
3. Preparation of the tartrate of the dextrorotatory (+)-amine A solution of impure (+)-amine (5 g - 0.023 M) 21~0229 , in 200 ml of 95% ethanol is treated with (+)-tartaric acid (3.47 g - 0.023 M). The mixture is heated to the reflux point and then left to stand at room temperature for about 3 hours. The precipitated tartrate is fil-05 tered off (5.5 g, 65%).
The tartrate thus obtained is decomposed with220 ml of 3 M sodium hydroxide. The aqueous phase is extracted with 3 times 200 ml of ethyl ether; the organic phase is dried over MgSO~, filtered and eva-porated to dryness to give 3.05 g of (+)-amine in the form of an oil. [~]D25 = +99 (c = 1.62; 95% EtOH); ee 81%.
4. Purification of the dextrorotatory (+)-amine The procedure is the same as for the levoro-tatory enantiomer, the oxalate of the (+)-amine being prepared by the addition of one equivalent of oxalic acid in 95% ethanol. The oxalate obtained is filtered off and then dried in air. Yield = 76%; [~]Dzs = +29 (c = 1.52; H2O); ee 97%.
The free amine is obtained by decomposing the oxalate with 3 M sodium hydroxide.
Preparation of levorotatory, dextrorotatory and racemic 1-(2-phthalimido-1-ethyl)-4-(1,2,3,4-tetrahydronaphth-1-yl)piperazine A mixture of levorotatory, dextrorotatory or racemic l-(1,2,3,4-tetrahydronaphth-1-yl)piperazine (10.8 g - 0.05 M), 2-bromoethylphthalimide (16.51 g -0.065 M), potassium carbonate (17.25 g - 0.125 M) and sodium iodide (1 g - 0.006 M) in 200 ml of acetonitrile is refluxed for 24 hours.
The solvent is evaporated off to dryness and the residue is taken up with water, extracted with ethyl acetate and washed with acid and base.
2I ~ 0229 --. . , The product is purified on a silica column using AcOEt/cyclohexane 35/65 as the eluent.
Levorotatory Dextrorotatory Racemic Yield 72% 73% 72%
05 M.p. 103 C 103 C 77 C
EX~I~PLE 16 Preparation of levorotatory, dextrorotatory and racemic 1-(2-amino-1-ethyl)-4-(1,2,3,4-tetrahydronaphth-1-yl)-piperazine A mixture of levorotatory, dextrorotatoryor racemic 1-(2-phthalimido-1-ethyl)-4-(1,2,3,4-tetra-hydronaphth-l-yl)piperazine (11.5 g - 0.029 M) and hydrazine hydrate (3.4 g - 0.068 M) in 200 ml of metha-nol is stirred magnetically at room temperature for 24hours.
The solvent is evaporated off under vacuum, 150 ml of 2 M HCl are added and the mixture is stirred magnetically for two hours. The solid formed is fil-tered off, the filtrate is neutralized with Na2CO3 andthe product is extracted with ethyl acetate to give a thick oil.
Levorotatory Dextrorotatory Racemic Yield 83% 79% 81%
The derivatives of formula (I) obtained from intermediates analogous to those of Examples 4 to 16, and containing the desired substituents, are collated in Table I below. Their yields and their melting points in the form of the base or a salt are reported in Table II below and their spectral data in Table III.
Derivatives of formula I
N l~(CH2 )n A~E~ (I) TABLE I
N- A n m R1 R2 R3 R4 Rs Empiricalformula NH-C0 2 1 H H Cl H HC22H26ClN3o NH-C0 2 1 H H ~ H HC2gH31N30 6 NH-C0 2 1 Cl H Cl H HCæH25Cl2N30 7 NH-C0 2 1 H0-CH3 0-CH3 0-CH3 HC2sH33N304 8 NH-C0 2 2 H H Cl H HC23H28ClN3 9 NH-C0 2 2 H H F H HC23H2gFN30 12 NH-C0 2 2 H H ~> H HC2gH33N30 13 NH-C0 2 2 Cl H Cl H HC23H27Cl2N3o NH-C0 2 3 H H Cl H HC24H30ClN30 17 NH-C0 2 3 H H aH3 H HC25H33N3 18 NH-C0 2 3 H H 0-CH3 H HC2sH33N302 19 NH-C0 2 3 H H <~ H HC30H35N30 NH-C0 2 3 Cl H Cl H HC24H29c12N3o 21 NH-C0 2 3 H0-CH3 0-CH3 0-CH3 HC~7H37N304 214022~
TABLE I ( continuation ) 24 NH-CO 3 3 H H F H HC2sH32FN3O
25 CO-NH 2 1 H H F H HCæH26FN3O
32 CO-NH 3 2 H H CF3 H HC2sH30F3N3 34 NH-CO 2 2 H H H H H C~H?gN3O
TABLE II
N- Yld 9~0 Mp~ C Mps C
S 75 153 2æ
9 54 145 æo Sl 134 210 11 56 149 l9S
lS 38 pasty 194 -.
TABLE II (continuation) 2152 pasty 214 24S5 oily 180 2954 oily 204 3053 pasty 236 3356,4oily 217 Mp" C: melting point of the base MPS C: melting point of the salt 2I~229 TABLE I I I
SPECTRAL DATA
IR ~cm~l) N- IH NMR (ppm) C= O NH
1 2,1(q,2H); 2,4-2,9(m,12H); 3,5(q,2H) 1633,5 3295 4,35(t,1H); 6,8 (NH); 7,1-7,9(DL8H) 2 2,1(q,2H); 2,4-3~mL12H);3,5(q,2H) 1634 3290,5 4,35(t,1H); 6,8~NH);7-7,9~mL8H) 3 2,1(q,2H); 2,37(s,3H); 2,5-3(~L12H); 3,5(q,2H) 1629,5 3299 4,35(t,1H); 6,8~NH); 7,1-7,8~mL8H) 4 2,1(q,2H); 2,4-3(m,12H); 3,5(q,2H); 3,8(s,3H) 1627 3320,7 4,3(t,1H); 6,8~NH); 6,8-7,8(m,8H) 2,1(q,2H); 2,4-3~mL12H); 3,5(q,2H); 1629 3295 4,35(t,1H); 6,8(NH); 7,2-8~mL13H) 6 2,1(q,2H); 2,45-3~mL12H); 3,5(q,2H) 1646,9 3280 4,3(t,1H); 6,9~NH); 7,1-7,7(nL7H) 7 2,1(q,2H); 2,4-3(m,12H); 3,5(q,2H) 1634 3283 3,85(s,qH); 4,3(t,1H); 6,8~NH); 7-7,4(m,6H) 8 1,85~L4H); 2,4-3~mL12H); 3,5(q,2H) 1633 3300 3,8(t,1H); 6,9(NH); 7-7,8(m,8H) 9 1,85~EL4H); 2,4-2,8(m,12H); 3,5(q,2H); 1634 3304 3,8(t,1H); 6,8~NH); 6,9-7,8(nl8H) 1,85(m,4H); 2,4(s,3H); 2,45-2,8(m,12H); 1632 3293 3,5(q,2H); 3,8(t,1H); 6,8(NH); 7-7,8(m,8H) 11 1,85(m,4H); 2,4-2,8(m,12H); 3,5(q,2H); 1627 3318 3,85(t,4H); 6,75(NH); 6,8-7,85(m,8H) 21~0229 -TABLE I I I ( continuation ) IR (cm~l) N- 'H NMR (ppm) C= O NH
12 1,85~EL4H);2,4-2,8~aL12H); 3,5(q,2H); 1635 3298 3,8(t,1H); 6,8(NH); 6,9-7,85(m,13H) 13 1,85(m,4H); 2,4-2,8~mL12H); 3,5(q,2H); 1635 3290 3,8(t,1H); 6,7~H); 6,9-7,8~EL7H) 14 1,85~EL4H~; 2,4-2,8~mL12H); 3,5(q,2H); 1634 3291 3.9(m,10H); 6,8(NH); 7-7,75 (m,6H) 1,5-2,2~CL6H~; 2,3-2,75(nL12H); 3,2(t,1H); 1639 3372 3,5(q,2H); 6,8(NH); 6,95-7,8(m,8H) 16 1,5-2,2(m,6H); 2,3-2,75(m,12H); 3,2(t,1H); 1643 3375 3,5(q,2H); 6,8(NH); 6,9-7,9(m,8H) 17 1,5-2,2~mL6H); 2,9(s,3H); 2,45-2,7~mL12H~; 1633 3312 3,2(t,1H); 3,5(q,2H~; 6,8(NH); 7-7,7~mL8H) 18 1,5-2,2~L6H); 2,4-2,75~mL12H); 3,2(t,1H); 1634 3341 3,5(q,2H); 3,85(s,3H); 6,6(NH); 6,8-7,85~EL8H) 19 1,5-2,2(m,6H); 2,4-2,8(m,12H); 3,2(t,1H); 1638 3350 3,5(q,2H); 6,8(NH); 6,9-7,9~mL13H) 1,5-2,2(m,6H); 2,4-2,8(m,12H); 3,2(t,1H); 1648 3443 3,5(q,2H); 6,9~NH); 7-7,75(m,7H) 21 1,5-2,2(m,6H); 2,4-2,75(m,12H); 3,2(t,1H); 1639 3363 3,5(q,2H); 3,9(s,9H); 6,9-7,25(m,7H~
22 1,65-2,2(m,4H); 2,4-3(EL12H); 3,5(q,2H); 1631 3344 4,3(t,1H); 6,85-7,95(m,8H); 8,4(NH~
23 1,65-2,15(m,6H); 2,4-2,95(m,12H); 1633 3321 3,4-4(m,3H); 6~9-8(m~8H); 8,45(NH) 21~02~9 TABLE III (continuation) IR (cm~l) N- 'H NMR (ppm) C= O NH
24 1,5-2,2~mL8H); 2,4-2,9(nL12H~; 1646 3334 3,1(t,1H); 3,5(q,2H); 6,95-7,95~mL8H); 8,4~NH) 2,1(q,2H); 2,4-3(m,14H); 4,4(t,1H); 1651 3285 6,8-7,6(nL8H); ll,OS~NH) 26 1,7-2,1(m,4H); 2,4-2,9(~L14H); 1654 3291 3,9(t,1H); 6,8-7,7(m,8H); ll,l~NH) 27 1,5-2,2~CL6H); 2,4-2,9~EL14H); 1683 3278 3,2(t,1H); 6,85-7,6(~L8H); ll,OS(NH) 28 1,7-2,15~m~4H); 2,35-3~14H); 4,3(t,1H); 1650 3277 6,85-7,6~mL8H); 9 (NH) 29 1,5-2,1~mL6H); 2,35-2,85~mL14H); 1646 3271 3,8(t,1H); 6,85-7,75(m,8H); 9,l~YH) 1,5-2,1~,8H); 2,3-2,8(m,14H); 1661 3261 3,2(t,1H); 6,85-7,7(m,8H); 9~NH) 31 1,6-2,15~mL4H); 2,4-2,9(~14H); 1686 3225 3,9(t,1H); 7-7,8(m8H); 11,45(NH) 32 1,5-2,15(~6H); 2,3-2,9~mL14H); 1667 3304 3,85(t,1H~; 7-7,8(m8H); 9,25(NH) 33 1,6-2,15(m,6H); 2,3(s,3H); 2,4-2,9(m,14H); 1655 3285 3,85(t,1H); 7-7,8(m,8H); 8,8(NH) 34 1,85(m,4H); 2,4-2,8(m,12H); 3,5(q,2H); 1636 3310 3,8(t,1H); 6,85(NH); 7-7,8(m,8H) 21~02~
PEIARMACOLOGICAL TESTS
The neuroleptic activity of the derivatives of formula (I) was evaluated by the following tests:
- Antagonism towards the effects induced by the injec-05 tion of 1 mg/kg of apomorphine (hypothermia, stereo-typies, redressments) - Increase in the immobility time in the tail suspen-sion test (TST) - Affinity (in vitro) for the D2 dopaminergic recep-tors.
As neuroleptics generally have a sedative and hypothermic character, the results obtained from the study of toxicity/Irwin symptoms will also be indicated in the Summary Table.
As correlations had been demonstrated between the anxiolytic activity of novel "non-benzodiazepinic"
derivatives, such as buspirone or ipsapirone, and their affinity for the 5-HTlA serotoninergic receptors, the compounds of the invention were evaluated on this basis. The values found on the other receptors are givenby way of indication and reflect the selectivity of the compounds of the invention.
1 - Interactions with apomorphine (1 mg/kg, administered subcutaneously) The test product is administered intraperi-toneally 60 min before the injection of apomorphine.
The apomorphine is injected subcutaneously at a rate of 1 mg/kg. The mice are then isolated in separate cages.
The redressments, the stereotypies (20 min after the injection of apomorphine) and the rectal tem-perature of the animals ( 30 min after the injection of apomorphine) are noted.
Conventional neuroleptics antagonize the symp-toms induced by apomorphine. Atypical neuroleptics can be ineffective on one or other of the three parameters, 21~022g or even on all three.
The results are expressed as follows:
- as the percentage change relative to the control for the redressments and the stereotypies, 05 - as the absolute change relative to the controls for the hypothermia.
The significance is indicated as follows: ns =
not significant; * = p < 0.05; ** = p < 0.01; *** = p <
0.001 according to the value of the Student test.
2 - Tail suspension test (TST) The tail suspension test described by STERU et al. (Prog. Neuropsycho. Pharmacol. Biol. Psychiat.
1987, 11, 659-671; Arch. Int. Pharmacodyn. Ther. 1987, 288 (1), 11-30) was prepared in order to detect psycho-tropic activities.
A rodent placed in an unpleasant situation withno obvious escape (suspended by the tail) rapidly reduces its evasive activity and then becomes immobile.
The test product is administered intraperi-toneally 60 min before the mouse is suspended.
Two parameters are measured:
- the period of immobility over 6 min - the power of the movements; this parameter, based on the energy expended by the animals, is independent of the duration of the activity.
10 animals are studied per dose. Antidepres-sants conventionally reduce the immobility time. Neu-roleptics tend to increase it.
The results are expressed as the percentage change relative to the untreated control.
The significance is indicated as follows: ns =
not significant; * = p < 0.05; ** = p < 0.01; *** = p <
O . 001 .
The results are reported in Table IV below:
21~02~9 -:
o C C~
c.~ E C * C C C C C c * * c * c * c O ~O ~ O ~ ~ o ~ ~ cr ~ cr~ ~ ~ ~O ~
+ + + + + + + + + +
~.
D C * C C C C C * C C * C * * *
a ~ ~ O ~ O ~
a ~+ ~+ ' ~+ ' ' ~+ ~+ + + ' ~+ + O+~ ~+
~ ~ ~ o o ~ ~ ~ `o ~ ~ ~t ~ l v~
~o ~ o o o o o o o o t` ~` o o t` l` o CL ~
~ -*c*****cc*c*c _ ~ ~ o o ~ ~; o o E- I I I + I + + I I + I I I I +
a .~
,_ C~ /
U~ ~
~ /
/ -Z
1'ABLE IV (continl~q~i!n.) TestsSedationHypothermia Dosetested Apomorphine TST
N- \ (i) (i) (ii) Hypoth.Redress.Stereotypy Immobility Power of movements 19 64 0 128 -1,4-C** 0% 13% +45% ns +10% ns 22 16 16 32 -2,5-C** 0% 6% +85%*~* -23% ns 23 64 16 32 -1,6-C ns 0% 0% +50%* +15% ns 24 16 32 32 -0,2-C ns 0% -6% +81%* -29% ,"
26 64 32 64 -2-C* * * 0% -13% +124%* * -12%
27 32 64 128 -0,1-C ns 0% 0% +51% ns +40%
29 32 32 64 -2,3-C*** -20% -13% +54% ns -44% ns 32 64 128 -1,0-C* 0% -41% +114%*** -46~o*
8 8 16 -0,3-C ns 0% -13% -8% ns +68%*
(i): dose in mg/kg at which activity appears in the Irwin test (ii): dosc tested in mg/kg (IP) in thc apomorphine and TST tests.
21~0229 -. . , 3 - Receptology The synaptic membranes are prepared by the method of JONES and MATUS (1980). The rats are decapi-tated and the brains (without the cerebellum) are 05 quickly removed.
The synaptic membranes are purified on a dis-continuous gradient of sucrose from a mitochondrial fraction lyzed by hypotonic shock, and are stored at The rat striatum membranes are prepared from different striata under the same conditions.
The membranes (100 ~g of proteins) are incu-bated in the presence of radioligands under the fol-lowing conditions reported in Table V below:
TABLE V
Receptor Labeled ligand Concentration Incubation (conditions) ~1 (3H) Prazozine0.25 nM 30 min/25 C
D2 (3H) Haloperidol 1 nM 45 min/25 C
5-HTlA (3H) 8-OH-DPAT 0.25 nM 60 min/25 C
5-HTz (3H) Ketanserine 0.5 nM 40 min/25 C
The measurements are made in the absence and presence of the derivatives to be studied. Each mole-cule is used at concentrations of 10-5, 10-7 and 10-9 M.
The results obtained with the various products are expressed as a percentage relative to the control without product.
All the derivatives of the invention exhibited - a 50% greater inhibition at a concentration of 10-5 M.
The effect of the products on the various 35 receptors, reported in Table VI below, is coded as 21~229 -follows:
+ : inhibition of between 30 and 50% at 10-7 M
++: inhibition greater than 50% at IO-7 M
\ Receptor ~1 Dz 5-HTz 5-HT,A
Derivative \
9 ++
+
17 +
+ ++
16 +
11 ++
2 + ++
4 +
13 +
18 ++
The pKi (-log Ki) values of some derivatives according to the invention, compared with buspirone and 8-hydroxy-di-n-propylaminotetralin (8-OH DPAT) taken as reference compounds, are given in Table VII below:
TABLE VII
\ Receptor C~lD2 5-HTz5-HTlA
Derivative \
(-) 8 6.35 6.32 5.568.40 (+) 8 5.08 6.16 5.426.68 9 7.10 7.17 5.938.82 (-) 9 6.90 7.17 5.869.30 (+) 9 6.15 6.12 5.887.30 34 6.82 6.96 6.158.96 (-) 34 6.72 6.88 9.40 8-oH DPAT 5.02 5.62 5.569.26 buspirone 5.87 7.35 5.908.13
5-HTz (3H) Ketanserine 0.5 nM 40 min/25 C
The measurements are made in the absence and presence of the derivatives to be studied. Each mole-cule is used at concentrations of 10-5, 10-7 and 10-9 M.
The results obtained with the various products are expressed as a percentage relative to the control without product.
All the derivatives of the invention exhibited - a 50% greater inhibition at a concentration of 10-5 M.
The effect of the products on the various 35 receptors, reported in Table VI below, is coded as 21~229 -follows:
+ : inhibition of between 30 and 50% at 10-7 M
++: inhibition greater than 50% at IO-7 M
\ Receptor ~1 Dz 5-HTz 5-HT,A
Derivative \
9 ++
+
17 +
+ ++
16 +
11 ++
2 + ++
4 +
13 +
18 ++
The pKi (-log Ki) values of some derivatives according to the invention, compared with buspirone and 8-hydroxy-di-n-propylaminotetralin (8-OH DPAT) taken as reference compounds, are given in Table VII below:
TABLE VII
\ Receptor C~lD2 5-HTz5-HTlA
Derivative \
(-) 8 6.35 6.32 5.568.40 (+) 8 5.08 6.16 5.426.68 9 7.10 7.17 5.938.82 (-) 9 6.90 7.17 5.869.30 (+) 9 6.15 6.12 5.887.30 34 6.82 6.96 6.158.96 (-) 34 6.72 6.88 9.40 8-oH DPAT 5.02 5.62 5.569.26 buspirone 5.87 7.35 5.908.13
Claims (13)
1. N-Cycloalkylpiperazine derivatives of formula (I) (I) in which:
- A is an amide group, or - R1, R2, R3, R4 and R5, which are identical or dif-ferent, are a hydrogen atom, a halogen atom, a C1-C6-alkyl group, a C1-C6-alkoxy group, a trifluoromethyl group or a phenyl group, - m is an integer between 1 and 3, - n is an integer equal to 2 or 3, and their pharmaceutically acceptable acid addition salts.
- A is an amide group, or - R1, R2, R3, R4 and R5, which are identical or dif-ferent, are a hydrogen atom, a halogen atom, a C1-C6-alkyl group, a C1-C6-alkoxy group, a trifluoromethyl group or a phenyl group, - m is an integer between 1 and 3, - n is an integer equal to 2 or 3, and their pharmaceutically acceptable acid addition salts.
2. Derivatives according to claim 1 of formula (I) in which R1, R2, R3, R4 and R5 are H, F or Cl.
3. Derivatives according to claim 1 or 2 of for-mula (I) in which at least one of the following con-ditions is fulfilled:
- A is an amide group , - R3 is a hydrogen atom or a halogen atom, preferably fluorine or chlorine, - m = 2 or 3, - n = 2.
- A is an amide group , - R3 is a hydrogen atom or a halogen atom, preferably fluorine or chlorine, - m = 2 or 3, - n = 2.
4. Derivatives according to any one of claims 1 to 3 which are levorotatory.
5. A method of preparing the derivatives of formula (I) according to claim 1, and their pharmaceu-tically acceptable acid addition salts, wherein a piperazine of formula (II):
(II) in which A, n, R1, R2, R3, R4 and R5 are as defined for (I) in claim 1, is condensed with a chlorinated derivative of formula (III):
(III) in which m is as defined for (I) in claim 1, in the presence of sodium or potassium carbonate and a catalytic amount of sodium or potassium iodide, in a ketone solvent, and the resulting compounds are converted to their pharmaceutically acceptable salts if appropriate.
(II) in which A, n, R1, R2, R3, R4 and R5 are as defined for (I) in claim 1, is condensed with a chlorinated derivative of formula (III):
(III) in which m is as defined for (I) in claim 1, in the presence of sodium or potassium carbonate and a catalytic amount of sodium or potassium iodide, in a ketone solvent, and the resulting compounds are converted to their pharmaceutically acceptable salts if appropriate.
6. A method of preparing the dextrorotatory or levorotatory derivatives of formula (I) according to claim 1 in optically pure form, and their pharmaceuti-cally acceptable acid addition salts, wherein the amines of formula (XV):
(XV) in which m is as defined for (I) in claim 1, are resolved by forming the diastereoisomeric salts with L-(+)-aspartic acid if it is desired to obtain levo-rotatory compound, and with L-(+)-tartaric acid if it is desired to obtain dextrorotatory compounds, the amines resolved in this way are reacted with a haloge-nated amide of formula (VIII):
(VIII) in which n, A, R1, R2, R3, R4 and R5 are as defined for (I) in claim 1 and X is a halogen atom, in an aromatic solvent, in the presence of triethylamine, and the resulting compounds are converted to their pharmaceutically acceptable salts if appropriate.
(XV) in which m is as defined for (I) in claim 1, are resolved by forming the diastereoisomeric salts with L-(+)-aspartic acid if it is desired to obtain levo-rotatory compound, and with L-(+)-tartaric acid if it is desired to obtain dextrorotatory compounds, the amines resolved in this way are reacted with a haloge-nated amide of formula (VIII):
(VIII) in which n, A, R1, R2, R3, R4 and R5 are as defined for (I) in claim 1 and X is a halogen atom, in an aromatic solvent, in the presence of triethylamine, and the resulting compounds are converted to their pharmaceutically acceptable salts if appropriate.
7. A method of preparing the derivatives according to claim 1 of formula (I) in which m and n are equal to 2, R1, R2, R4 and R5 are a hydrogen, R3 is a hydrogen atom or halogen atom, preferably fluorine or chlorine, and A = , in racemic or optically pure form, and their pharmaceutically acceptable acid addition salts, wherein the racemic or enantiomerically pure aminoethylpiperazine (XVIII):
(XVIII) is condensed with the benzoyl chlorides (XIIIa):
( XIIIa) in which R3 is as defined above, and the resulting compounds are converted to their pharmaceutically acceptable salts if appropriate.
(XVIII) is condensed with the benzoyl chlorides (XIIIa):
( XIIIa) in which R3 is as defined above, and the resulting compounds are converted to their pharmaceutically acceptable salts if appropriate.
8. Derivatives according to any one of claims 1 to 4 for their use as agents active on the central nervous system.
9. Derivatives according to claim 8 for their use as neuroleptics.
10. Derivatives according to any one of claims 1 to 4 for their use as 5-HT1A agonists.
11. Pharmaceutical compositions in which a deriva-tive according to any one of claims 1 to 4, or one of its pharmaceutically acceptable acid addition salts, is present as the active principle, in association with a pharmaceutically acceptable vehicle.
12. Use of a derivative of formula (I) according to any one of claims 1 to 4, or one of its pharmaceuti-cally acceptable acid addition salts, for the prepara-tion of drugs active on the central nervous system.
13 . Use of a derivative of formula (I) according to any one of claims 1 to 4 as a pharmacological reagent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9208808A FR2693722B1 (en) | 1992-07-16 | 1992-07-16 | N-cycloalkylpiperazine derivatives, process for obtaining them and pharmaceutical compositions containing them. |
FR9208808 | 1992-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2140229A1 true CA2140229A1 (en) | 1994-02-03 |
Family
ID=9431966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002140229A Abandoned CA2140229A1 (en) | 1992-07-16 | 1993-07-15 | N-cycloalkylpiperazine derivatives, methods of obtaining them and pharmaceutical compositions containing them |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0649419A1 (en) |
JP (1) | JPH08501285A (en) |
AU (1) | AU4573793A (en) |
CA (1) | CA2140229A1 (en) |
FR (1) | FR2693722B1 (en) |
WO (1) | WO1994002473A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281215B1 (en) | 1996-12-18 | 2001-08-28 | Merck Patent Gmbh | 4-(1-piperazinyl) benzoic acid derivatives, process for preparing them and their therapeutic applications |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5395835A (en) * | 1994-03-24 | 1995-03-07 | Warner-Lambert Company | Naphthalamides as central nervous system agents |
US5472966A (en) * | 1995-03-29 | 1995-12-05 | Bristol-Myers Squibb Company | Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines |
CA2175395A1 (en) * | 1995-06-02 | 1996-12-03 | Ronald J. Mattson | Melatonergic indanyl piperazines or homopiperazines |
FR2763334A1 (en) * | 1997-05-13 | 1998-11-20 | Lipha | Piperazino alkyl anthranilic acid amide |
AU9650398A (en) | 1997-11-07 | 1999-05-31 | Daiichi Pharmaceutical Co., Ltd. | Piperazine-cyclodextrin complexes |
US20040077654A1 (en) * | 2001-01-15 | 2004-04-22 | Bouillot Anne Marie Jeanne | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR6452M (en) * | 1967-03-10 | 1968-11-12 | ||
ES8308553A1 (en) * | 1982-06-17 | 1983-09-01 | Ferrer Int | Piperazine derivatives, a process for preparing them and pharmaceutical compositions. |
US5028610A (en) * | 1987-03-18 | 1991-07-02 | Sankyo Company Limited | N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use |
NZ231631A (en) * | 1988-12-08 | 1992-07-28 | Duphar Int Res | Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions |
FR2655988B1 (en) * | 1989-12-20 | 1994-05-20 | Adir Cie | NOVEL DERIVATIVES OF NAPHT-1-YL PIPERAZINE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2664592B1 (en) * | 1990-07-10 | 1994-09-02 | Adir | NOVEL DERIVATIVES OF PIPERIDINE, TETRAHYDROPYRIDINE AND PYRROLIDINE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
-
1992
- 1992-07-16 FR FR9208808A patent/FR2693722B1/en not_active Expired - Fee Related
-
1993
- 1993-07-15 CA CA002140229A patent/CA2140229A1/en not_active Abandoned
- 1993-07-15 JP JP6503935A patent/JPH08501285A/en active Pending
- 1993-07-15 AU AU45737/93A patent/AU4573793A/en not_active Abandoned
- 1993-07-15 WO PCT/FR1993/000723 patent/WO1994002473A1/en not_active Application Discontinuation
- 1993-07-15 EP EP93916003A patent/EP0649419A1/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281215B1 (en) | 1996-12-18 | 2001-08-28 | Merck Patent Gmbh | 4-(1-piperazinyl) benzoic acid derivatives, process for preparing them and their therapeutic applications |
Also Published As
Publication number | Publication date |
---|---|
JPH08501285A (en) | 1996-02-13 |
WO1994002473A1 (en) | 1994-02-03 |
FR2693722B1 (en) | 1994-10-14 |
EP0649419A1 (en) | 1995-04-26 |
AU4573793A (en) | 1994-02-14 |
FR2693722A1 (en) | 1994-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2436225C (en) | N-(arylsulphonyl)beta-amino acid derivatives comprising a substituted aminomethyl group, process for preparing them and pharmaceutical compositions containing them | |
AU657799B2 (en) | Novel 4-arylpiperazines and 4-arylpiperidines | |
FI91862C (en) | Process for the preparation of 2- [2- [4 - / (4-chlorophenyl) phenylmethyl] -1-piperazinyl] ethoxy] acetic acid and its dihydrochloride | |
US4605655A (en) | Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives | |
CA2015473C (en) | Triphenylmethane derivatives | |
CS381991A3 (en) | Novel n-arylpiperazine alkane amides, process of their preparation and pharmaceuticals based thereon | |
US4994460A (en) | Agents for treatment of brain ischemia | |
JP2006342190A (en) | Enantiomer of 1-[(4-chlorophenyl)phenylmethyl]piperazine and its producing method | |
JPH0518830B2 (en) | ||
CA2541066C (en) | Derivatives of indanyl-piperazines, the process for preparing them and the pharmaceutical compounds that contain them | |
EP1608635B1 (en) | Phenyl sulfone derivatives and their use in the treatment of cns disorders | |
US4604392A (en) | 2-substituted benzofuran derivatives useful in treating cardiac arrhythmic, histaminic and tussive conditions | |
HU190827B (en) | Process for preparing 2-/4/-/4,4-dialkyl-1,2,6-piperidindion-1-yl/-butyl/-1-piperazinyl/-pyridines | |
CA1084490A (en) | Synthesis for the preparation of tetracyclic compounds | |
NO311615B1 (en) | New substituted [2- (1-piperazinyl) ethoxy] methyl compounds, process for the preparation and use of such | |
JP2000086603A (en) | Cinnamic acid amide derivative and 3-phenylpropionic acid amide derivative | |
CA2140229A1 (en) | N-cycloalkylpiperazine derivatives, methods of obtaining them and pharmaceutical compositions containing them | |
NO311515B1 (en) | Tetrahydrobenzindole compounds, and pharmaceutical preparations containing such compounds | |
US4882329A (en) | Alkoxyphenylindolinone derivatives, medicaments containing them and their use | |
CA2053709C (en) | Piperazine derivatives | |
US4957927A (en) | (Diarylmethoxy alkyl)-1-pyrrolidines and piperidines having cardiovascular activity | |
US3000892A (en) | 1-aroylalkyl-4-aroylpiperazines | |
US5364849A (en) | 1-[3 or 4-[1-[4-piperazinyl]]-2 arylpropionyl or butryl]-heterocyclic derivatives | |
KR20040007672A (en) | Novel Phenylalkyl Diamine and Amide Analogs | |
CA2000060A1 (en) | Substituted aromatic compounds having an action on the central nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20010716 |